thalidomide has been researched along with Disease Exacerbation in 316 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)." | 9.24 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017) |
| "On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy." | 9.24 | The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. ( Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 9.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "The combination of lenalidomide and dexamethasone is an established treatment for patients with multiple myeloma (MM)." | 9.24 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. ( Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C, 2017) |
| "The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma." | 9.22 | Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. ( Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM, 2016) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 9.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM)." | 9.19 | A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. ( Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I, 2014) |
| "In lower-risk myelodysplastic syndromes (MDS) with del(5q), lenalidomide induces erythroid responses associated with better survival." | 9.17 | Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. ( Alati, C; Alimena, G; Aloe Spiriti, MA; Balleari, E; Breccia, M; Cortelezzi, A; D'Errigo, MG; Finelli, C; Galimberti, S; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, G; Poloni, A; Rodà, F; Sanpaolo, G; Specchia, G; Volpe, A, 2013) |
| "Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma." | 9.17 | Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF, 2013) |
| "In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment." | 9.17 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m2 days 1 and 2 of cycle 1 and 27 mg/m2 days 8, 9, 15, 16, and thereafter; lenalidomide 25 mg days 1 to 21; and dexamethasone 40 mg once weekly on 28-day cycles." | 9.17 | Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M, 2013) |
| "We report results of a phase II trial of combination of melphalan, lenalidomide, and dexamethasone for the treatment of immunoglobulin light chain (AL) amyloidosis." | 9.17 | Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. ( Patel, JM; Sanchorawala, V; Seldin, DC; Shelton, AC; Sloan, JM; Zeldis, JB, 2013) |
| "Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma." | 9.16 | Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. ( Avet-Loiseau, H; Baylon, HG; Bladé, J; Caravita, T; Facon, T; Glasmacher, A; Goranov, S; Hajek, R; Hillengass, J; Hulin, C; Kropff, M; Kueenburg, E; Liebisch, P; Lucy, L; Moehler, TM; Pattou, C; Robak, T; Zerbib, R, 2012) |
| "We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous stem cell transplantation (ASCT) in patients with multiple myeloma." | 9.16 | Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. ( Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH, 2012) |
| "Here we report the efficacy, safety and health-related quality-of-life (HRQoL) associated with long-term lenalidomide and dexamethasone (Len + Dex) treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the Spanish cohort of the MM-018 study." | 9.16 | Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. ( Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A, 2012) |
| "Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. ( Cheng, AL; Hsiao, CH; Hsu, C; Hsu, CH; Huang, CC; Lee, KD; Lin, ZZ; Lu, YS; Shao, YY; Shen, YC, 2012) |
| "This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 9.16 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C, 2012) |
| "In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethasone alone." | 9.15 | Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB, 2011) |
| "The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM)." | 9.15 | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. ( Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR, 2011) |
| "Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting." | 9.14 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. ( Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 9.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 9.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "Bortezomib-based regimens have significant activities in multiple myeloma (MM)." | 9.14 | A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. ( Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK, 2010) |
| "There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases." | 9.13 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008) |
| " Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM)." | 9.13 | A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. ( Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW, 2008) |
| "Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM)." | 9.13 | Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. ( Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH, 2008) |
| "The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown." | 9.13 | Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. ( Bladé, J; Catalano, J; Hussein, M; Jedrzejczak, W; Knight, R; Lucy, L; Olesnyckyj, M; Rajkumar, SV; Rosiñol, L; Yu, Z; Zeldis, JB, 2008) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 9.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma." | 9.12 | Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Capelli, D; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Montanari, M; Offidani, M; Olivieri, A; Piersantelli, MN; Polloni, C; Poloni, A; Rupoli, S; Scortechini, AR; Visani, G, 2006) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma." | 9.12 | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. ( Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB, 2007) |
| "Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma." | 9.12 | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. ( Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2007) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 9.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation." | 9.11 | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. ( Alsina, M; Anderson, K; Blood, E; Bosch, J; Dalton, W; Davies, F; Desikan, R; Doss, D; Freeman, A; Hideshima, T; Jagannath, S; Knight, R; Mitsiades, C; Patin, J; Richardson, P; Schlossman, R; Weller, E; Zeldis, J, 2004) |
| "The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas." | 9.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "This study was designed to estimate the percentage of objective tumor responses, toxicity profile, and obtain additional information about the plasma pharmacokinetics of thalidomide in patients with refractory and progressing metastatic colorectal cancer." | 9.10 | Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. ( Cancela, AI; Costa, TD; Dal Lago, L; Di Leone, LP; Fernandes, SA; Jung, KT; Richter, MF; Rodrigues, AC; Schwartsmann, G, 2003) |
| " Thalidomide was well tolerated, with constipation and sedation being the major toxicities." | 9.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "To assess response of recurrent malignant gliomas to thalidomide." | 9.09 | Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001) |
| "Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM)." | 8.95 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. ( Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z, 2017) |
| " We present two cases of patients diagnosed with lupus nephritis (LN) who demonstrated persistent proteinuria while on standard treatments that markedly improved after addition of thalidomide (THD)." | 8.95 | Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis. ( Carter, JD; Patel, AA; Raturi, R, 2017) |
| "On August 5, 2013, a marketing authorization valid throughout the European Union (EU) was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy." | 8.91 | The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. ( Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A, 2015) |
| "Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA)." | 8.90 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma. ( Scott, LJ, 2014) |
| "Lenalidomide is an IMiDs® oral immunomodulatory compound developed for the treatment of patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS)." | 8.88 | The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. ( Fenaux, P; Freeman, J; Palumbo, A; Weiss, L, 2012) |
| "Lenalidomide is an immunomodulatory drug (IMiD) with erythropoietic activity in myelodysplastic syndromes (MDS) that is karyotype dependent." | 8.85 | Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. ( List, A, 2009) |
| "The aim of the multi-centre retrospective study was to evaluate the efficacy and safety of lenalidomide (LEN) therapy in patients with resistant or relapsed multiple myeloma (MM) as well as in patients with stable disease (LEN used due to neurological complications)." | 7.83 | Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. ( Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A, 2016) |
| "Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear." | 7.83 | Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. ( Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH, 2016) |
| "The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM)." | 7.81 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. ( Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A, 2015) |
| "The aim of this study was to assess the safety and efficacy of lenalidomide (Len), with the dose adjusted according to the renal function, plus low-dose dexamethasone (Dex) in older patients with bortezomib (Bor)-resistant multiple myeloma (MM)." | 7.81 | Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. ( Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S, 2015) |
| "A consecutive cohort of pretreated patients with advanced colorectal cancer were treated with thalidomide combined with chemotherapy." | 7.81 | Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. ( Deng, LC; Gu, HG; Gu, M; Huang, XE; Ji, ZQ; Li, L; Liu, MY; Liu, Y; Qian, T; Shen, HL; Wang, L; Yan, XC, 2015) |
| "The impact of lenalidomide treatment on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear." | 7.80 | Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. ( Arilla, MJ; Arrizabalaga, B; Azaceta, G; Bailén, A; Bargay, J; Brunet, S; Cerveró, C; de Paz, R; Del Cañizo, C; Diez-Campelo, M; Falantes, J; García-Pintos, M; Lorenzo, I; Luño, E; Marco-Betes, V; Nomdedeu, B; Osorio, S; Ramos, F; Sánchez-García, J; Sanz, GF; Serrano-López, J; Such, E; Tormo, M; Valcárcel, D; Xicoy, B, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 7.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 7.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond." | 7.79 | Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. ( Alvarez, S; Arenillas, L; Calasanz, MJ; Cervera, J; Cigudosa, JC; Costa, D; Del Rey, M; Diez-Campelo, M; Florensa, L; González-Martínez, T; Hernández, JM; Ibáñez, M; Jerez, A; Larráyoz, MJ; Lumbreras, E; Maciejewski, J; Mallo, M; Marugán, I; Nomdedeu, M; Pedro, C; Solé, F; Such, E, 2013) |
| "Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression." | 7.79 | Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. ( Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S, 2013) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 7.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents." | 7.78 | Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012) |
| "Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), concerns have been raised over the fact that this drug could trigger progression to acute myeloid leukemia in some patients." | 7.78 | Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. ( Adès, L; Banos, A; Blanc, M; Bouscary, D; Bresler, AG; Cabrol, MP; Chevret, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Kelaidi, C; Lamy, T; Le Bras, F; Sebert, M; Turlure, P; Vey, N; Visanica, S; Wattel, E, 2012) |
| "Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM)." | 7.78 | Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. ( Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C, 2012) |
| "Two pivotal, phase III, randomised, placebo-controlled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma." | 7.78 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D, 2012) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 7.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide." | 7.73 | Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. ( Goldenberg, A; Lehrer, D; Liebes, L; Mandeli, J; Schwartz, JD; Schwartz, M; Sung, M; Volm, M, 2005) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 7.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine." | 7.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma." | 7.72 | Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Iturria, NL; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "After the second recurrence of spinal seeding in hemangioblastoma not associated to von-Hippel-Lindau disease, we treated an adult female patient with thalidomide 200 mg orally/day at night for longer than 1 year." | 7.72 | Stabilization of a progressive hemangioblastoma under treatment with thalidomide. ( Birner, P; Czech, T; Dieckmann, K; Fazeny-Dörner, B; Hainfellner, JA; Marosi, C; Piribauer, M; Prayer, D; Weinländer, G, 2004) |
| "Thalidomide has been shown to be effective in approximately 30% of patients with refractory or advanced multiple myeloma (MM)." | 7.72 | Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. ( Balleari, E; Falcone, A; Ghio, R; Musto, P, 2004) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 7.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 7.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with." | 6.84 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 6.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 6.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Thalidomide and TACE were commonly associated with nonhematologic side effects, with fatigue and constipation being prominent." | 6.79 | Chronic thalidomide and chemoembolization for hepatocellular carcinoma. ( Christos, PJ; Goldenberg, AS; Hochster, HS; Muggia, FM; Ng, J; Sparano, J; Sung, MW; Wu, J, 2014) |
| "The lenalidomide dose was 25 mg/day, and was adjusted according to baseline renal function." | 6.78 | A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ( Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB, 2013) |
| "For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop." | 6.78 | Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. ( Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF, 2013) |
| "Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM)." | 6.78 | A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. ( Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE, 2013) |
| "Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study." | 6.76 | A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. ( Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M, 2011) |
| " Food and Drug Administration (FDA) on June 29, 2006, for use in combination with dexamethasone in patients with multiple myeloma (MM) who have received at least one prior therapy." | 6.73 | Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. ( Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G, 2008) |
| "Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma." | 6.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 6.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 6.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 6.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| "The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents." | 6.71 | Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. ( Abbruzzese, JL; Brown, TD; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Zeldis, JB, 2005) |
| "Thalidomide is a well-tolerated drug that may have some activity in the treatment of recurrent glioblastoma." | 6.70 | Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. ( Bell, DR; Biggs, M; Boyle, FM; Cook, R; Levi, JA; Little, N; Marx, GM; McCowatt, S; Pavlakis, N; Wheeler, HR, 2001) |
| "Lenalidomide also has meaningful clinical activity in lower-risk patients without deletion 5q." | 6.46 | Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? ( Komrokji, RS; Lancet, JE; List, AF, 2010) |
| "When thalidomide was added to standard, non-transplantation myeloma therapy, overall survival (OS) improved (HR 0." | 6.44 | A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. ( Haynes, AE; Herst, JA; Hicks, LK; Imrie, K; Meyer, RM; Reece, DE; Walker, IR, 2008) |
| "Thalidomide is a drug that has been reported to inhibit angiogenesis and reduce VEGF production by downregulating VEGF expression." | 5.48 | Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice. ( Cai, DZ; Fang, H; Li, L; Song, JL, 2018) |
| "Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways." | 5.43 | A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. ( Cannizzaro, MV; Caposiena, D; Chimenti, S; Chiricozzi, A; Garofalo, V; Saraceno, R, 2016) |
| "Lenalidomide was not associated with AML transformation in the cohort analysis (HR = 0." | 5.43 | Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. ( Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q, 2016) |
| "Lenalidomide was discontinued after 10 days due to exacerbation of renal dysfunction." | 5.42 | Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included." | 5.37 | Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. ( Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D, 2011) |
| "Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly." | 5.36 | Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S, 2010) |
| "The phase 3 FIRST trial demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) with an immune-stimulatory agent, lenalidomide, in combination with low-dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.34 | Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. ( Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D, 2020) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | 5.34 | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 5.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| "EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)." | 5.24 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017) |
| "Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed." | 5.24 | Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). ( Beyne-Rauzy, O; Deeg, HJ; Del Cañizo, C; Fenaux, P; Giagounidis, A; Greenberg, PL; Guerci-Bresler, A; Hellström-Lindberg, E; List, AF; Mittelman, M; Muus, P; Nimer, SD; Powell, BL; Sekeres, MA; Selleslag, D; Shammo, JM; Skikne, B; Yu, X, 2017) |
| " Food and Drug Administration granted regular approval to daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. ( Bhatnagar, V; Farrell, AT; Goldberg, KB; Gormley, NJ; Luo, L; Ma, L; McKee, AE; Pazdur, R; Shen, G; Shen, YL; Shord, S; Sridhara, R; Subramaniam, S, 2017) |
| "On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy." | 5.24 | The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. ( Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "The combination of lenalidomide and dexamethasone is an established treatment for patients with multiple myeloma (MM)." | 5.24 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. ( Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C, 2017) |
| "The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma." | 5.22 | Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. ( Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM, 2016) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| " Aspirin or heparin was recommended for patients at high thrombosis risk." | 5.20 | Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). ( Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Giguere, JK; Johnson, J; Jung, SH; Leonard, JP; Pitcher, BN, 2015) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 5.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM)." | 5.19 | A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. ( Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I, 2014) |
| "In lower-risk myelodysplastic syndromes (MDS) with del(5q), lenalidomide induces erythroid responses associated with better survival." | 5.17 | Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. ( Alati, C; Alimena, G; Aloe Spiriti, MA; Balleari, E; Breccia, M; Cortelezzi, A; D'Errigo, MG; Finelli, C; Galimberti, S; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, G; Poloni, A; Rodà, F; Sanpaolo, G; Specchia, G; Volpe, A, 2013) |
| "Carfilzomib, a selective proteasome inhibitor, has shown safety and efficacy in relapsed and/or refractory multiple myeloma." | 5.17 | Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF, 2013) |
| "The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF." | 5.17 | Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. ( Hilliard, ME; Horton, MR; Lechtzin, N, 2013) |
| "Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown." | 5.17 | Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. ( Badillo, M; Bejarano, M; Champlin, R; Chen, Y; Cheng, N; Desai, M; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hosing, C; Kwak, L; Neelapu, SS; Newberry, KJ; Oki, Y; Pro, B; Romaguera, J; Shah, J; Thomas, S; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zhang, L, 2013) |
| "In this open-label, multicentre, randomised phase 3 study, eligible patients had proven malignant pleural or peritoneal mesothelioma and had received a minimum of four cycles of first-line treatment containing at least pemetrexed, with or without cisplatin or carboplatin, and had not progressed on this treatment." | 5.17 | Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. ( Baas, P; Buikhuisen, WA; Burgers, JA; Custers, FL; Gans, SJ; Groen, HJ; Korse, CM; Nowak, AK; Pavlakis, N; Schouwink, JH; Schramel, FM; Strankinga, WF; van Klaveren, RJ; Vincent, AD, 2013) |
| "We previously reported a phase 1b dose-escalation study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in relapsed or progressive multiple myeloma where the maximum planned dose (MPD) was carfilzomib 20 mg/m2 days 1 and 2 of cycle 1 and 27 mg/m2 days 8, 9, 15, 16, and thereafter; lenalidomide 25 mg days 1 to 21; and dexamethasone 40 mg once weekly on 28-day cycles." | 5.17 | Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. ( Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M, 2013) |
| "We report results of a phase II trial of combination of melphalan, lenalidomide, and dexamethasone for the treatment of immunoglobulin light chain (AL) amyloidosis." | 5.17 | Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. ( Patel, JM; Sanchorawala, V; Seldin, DC; Shelton, AC; Sloan, JM; Zeldis, JB, 2013) |
| "Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma." | 5.16 | Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. ( Avet-Loiseau, H; Baylon, HG; Bladé, J; Caravita, T; Facon, T; Glasmacher, A; Goranov, S; Hajek, R; Hillengass, J; Hulin, C; Kropff, M; Kueenburg, E; Liebisch, P; Lucy, L; Moehler, TM; Pattou, C; Robak, T; Zerbib, R, 2012) |
| "We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous stem cell transplantation (ASCT) in patients with multiple myeloma." | 5.16 | Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. ( Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH, 2012) |
| "Here we report the efficacy, safety and health-related quality-of-life (HRQoL) associated with long-term lenalidomide and dexamethasone (Len + Dex) treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the Spanish cohort of the MM-018 study." | 5.16 | Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. ( Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A, 2012) |
| "Thalidomide has been shown to have antitumor activity in some patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. ( Cheng, AL; Hsiao, CH; Hsu, C; Hsu, CH; Huang, CC; Lee, KD; Lin, ZZ; Lu, YS; Shao, YY; Shen, YC, 2012) |
| "This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 5.16 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C, 2012) |
| "In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethasone alone." | 5.15 | Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB, 2011) |
| "The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM)." | 5.15 | Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. ( Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR, 2011) |
| "Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting." | 5.14 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. ( Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 5.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 5.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "Bortezomib-based regimens have significant activities in multiple myeloma (MM)." | 5.14 | A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. ( Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK, 2010) |
| "We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM)." | 5.14 | Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. ( Detweiler-Short, K; Dispenzieri, A; Gertz, MA; Greipp, PR; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Russell, SJ; Vincent Rajkumar, S; Witzig, TE; Zeldenrust, SR, 2010) |
| "There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases." | 5.13 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008) |
| " Thalidomide, an antiangiogenic agent, may play a role in the treatment of glioblastoma multiforme (GBM)." | 5.13 | A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. ( Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW, 2008) |
| "Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM)." | 5.13 | Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. ( Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH, 2008) |
| "The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown." | 5.13 | Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. ( Bladé, J; Catalano, J; Hussein, M; Jedrzejczak, W; Knight, R; Lucy, L; Olesnyckyj, M; Rajkumar, SV; Rosiñol, L; Yu, Z; Zeldis, JB, 2008) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 5.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma." | 5.12 | Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Capelli, D; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Giuliodori, L; Leoni, P; Marconi, M; Montanari, M; Offidani, M; Olivieri, A; Piersantelli, MN; Polloni, C; Poloni, A; Rupoli, S; Scortechini, AR; Visani, G, 2006) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma." | 5.12 | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. ( Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB, 2007) |
| "Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma." | 5.12 | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. ( Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2007) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 5.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation." | 5.11 | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. ( Alsina, M; Anderson, K; Blood, E; Bosch, J; Dalton, W; Davies, F; Desikan, R; Doss, D; Freeman, A; Hideshima, T; Jagannath, S; Knight, R; Mitsiades, C; Patin, J; Richardson, P; Schlossman, R; Weller, E; Zeldis, J, 2004) |
| " We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease." | 5.10 | Thalidomide as initial therapy for early-stage myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Iturria, N; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas." | 5.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "This study was designed to estimate the percentage of objective tumor responses, toxicity profile, and obtain additional information about the plasma pharmacokinetics of thalidomide in patients with refractory and progressing metastatic colorectal cancer." | 5.10 | Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. ( Cancela, AI; Costa, TD; Dal Lago, L; Di Leone, LP; Fernandes, SA; Jung, KT; Richter, MF; Rodrigues, AC; Schwartsmann, G, 2003) |
| " Thalidomide was well tolerated, with constipation and sedation being the major toxicities." | 5.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "To assess response of recurrent malignant gliomas to thalidomide." | 5.09 | Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001) |
| "Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM)." | 4.95 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. ( Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z, 2017) |
| " We present two cases of patients diagnosed with lupus nephritis (LN) who demonstrated persistent proteinuria while on standard treatments that markedly improved after addition of thalidomide (THD)." | 4.95 | Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis. ( Carter, JD; Patel, AA; Raturi, R, 2017) |
| "On August 5, 2013, a marketing authorization valid throughout the European Union (EU) was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy." | 4.91 | The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. ( Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A, 2015) |
| "Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA)." | 4.90 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma. ( Scott, LJ, 2014) |
| "The outcomes and management of multiple myeloma (MM) in the United States have changed dramatically over the past 15 years with the approval by the US Food and Drug Administration (FDA) of 6 new drugs (thalidomide, lenalidomide, bortezomib, pegylated liposomal doxorubicin [Doxil], carfilzomib, and pomalidomide)." | 4.90 | Novel drug combinations for the management of relapsed/refractory multiple myeloma. ( Lonial, S; Usmani, SZ, 2014) |
| "Lenalidomide is an IMiDs® oral immunomodulatory compound developed for the treatment of patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS)." | 4.88 | The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes. ( Fenaux, P; Freeman, J; Palumbo, A; Weiss, L, 2012) |
| "Novel agents such as thalidomide, bortezomib, and lenalidomide have improved outcomes and extended survival in patients with relapsed and/or refractory multiple myeloma (RRMM)." | 4.88 | Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? ( Ludwig, H; Sonneveld, P, 2012) |
| "Lenalidomide is an immunomodulatory drug (IMiD) with erythropoietic activity in myelodysplastic syndromes (MDS) that is karyotype dependent." | 4.85 | Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. ( List, A, 2009) |
| " Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19." | 3.96 | Outcome of COVID-19 in multiple myeloma patients in relation to treatment. ( Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH, 2020) |
| "A high proportion of patients with lower-risk del(5q) myelodysplastic syndromes will respond to treatment with lenalidomide." | 3.85 | Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. ( Boultwood, J; Dimitriou, M; Douagi, I; Giai, V; Grandien, A; Hellström-Lindberg, E; Jacobsen, SE; Jädersten, M; Jansson, M; Karimi, M; LeBlanc, K; Neuberg, DS; Pellagatti, A; Saft, L; Scharenberg, C; Woll, PS, 2017) |
| "The aim of the multi-centre retrospective study was to evaluate the efficacy and safety of lenalidomide (LEN) therapy in patients with resistant or relapsed multiple myeloma (MM) as well as in patients with stable disease (LEN used due to neurological complications)." | 3.83 | Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group. ( Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A, 2016) |
| "Although the antimyeloma effect of lenalidomide is associated with activation of the immune system, the exact in vivo immunomodulatory mechanisms of lenalidomide combined with low-dose dexamethasone (Len-dex) in refractory/relapsed multiple myeloma (RRMM) patients remain unclear." | 3.83 | Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma. ( Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH, 2016) |
| "The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM)." | 3.81 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. ( Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A, 2015) |
| "The aim of this study was to assess the safety and efficacy of lenalidomide (Len), with the dose adjusted according to the renal function, plus low-dose dexamethasone (Dex) in older patients with bortezomib (Bor)-resistant multiple myeloma (MM)." | 3.81 | Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma. ( Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S, 2015) |
| "Lenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q(-)." | 3.81 | Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. ( Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R, 2015) |
| "A consecutive cohort of pretreated patients with advanced colorectal cancer were treated with thalidomide combined with chemotherapy." | 3.81 | Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. ( Deng, LC; Gu, HG; Gu, M; Huang, XE; Ji, ZQ; Li, L; Liu, MY; Liu, Y; Qian, T; Shen, HL; Wang, L; Yan, XC, 2015) |
| "Lenalidomide is the approved treatment for patients with red blood cell (RBC) transfusion-dependent lower-risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q))." | 3.80 | Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. ( Bennett, JM; Fu, T; Giagounidis, A; Knight, RD; List, AF; Nimer, SD; Sekeres, MA; Shammo, JM; Skikne, B, 2014) |
| "Three cost effectiveness models for the treatment of multiple myeloma, were compared that had been developed to inform resource allocation in the UK for the chemotherapy regimens bortezomib, melphalan and prednisolone (BMP); and melphalan, prednisolone and thalidomide (MPT) versus melphalan and prednisolone (MP)." | 3.80 | Comparative cost-effectiveness models for the treatment of multiple myeloma. ( Bryant, J; Clegg, A; Cooper, K; Picot, J, 2014) |
| "The impact of lenalidomide treatment on long-term outcomes of patients with lower risk myelodysplastic syndromes (MDS) and chromosome 5q deletion (del(5q)) is unclear." | 3.80 | Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. ( Arilla, MJ; Arrizabalaga, B; Azaceta, G; Bailén, A; Bargay, J; Brunet, S; Cerveró, C; de Paz, R; Del Cañizo, C; Diez-Campelo, M; Falantes, J; García-Pintos, M; Lorenzo, I; Luño, E; Marco-Betes, V; Nomdedeu, B; Osorio, S; Ramos, F; Sánchez-García, J; Sanz, GF; Serrano-López, J; Such, E; Tormo, M; Valcárcel, D; Xicoy, B, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 3.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 3.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond." | 3.79 | Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. ( Alvarez, S; Arenillas, L; Calasanz, MJ; Cervera, J; Cigudosa, JC; Costa, D; Del Rey, M; Diez-Campelo, M; Florensa, L; González-Martínez, T; Hernández, JM; Ibáñez, M; Jerez, A; Larráyoz, MJ; Lumbreras, E; Maciejewski, J; Mallo, M; Marugán, I; Nomdedeu, M; Pedro, C; Solé, F; Such, E, 2013) |
| "Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression." | 3.79 | Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. ( Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S, 2013) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 3.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "Data comparing long-term outcomes in lenalidomide-treated and untreated patients with myelodysplastic syndromes (MDS) with del(5q) are limited." | 3.79 | Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. ( Backstrom, J; Brandenburg, NA; Fenaux, P; Germing, U; Giagounidis, AA; Glasmacher, A; Hasford, J; Kuendgen, A; Lauseker, M; List, AF, 2013) |
| "The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents." | 3.78 | Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012) |
| "Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), concerns have been raised over the fact that this drug could trigger progression to acute myeloid leukemia in some patients." | 3.78 | Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. ( Adès, L; Banos, A; Blanc, M; Bouscary, D; Bresler, AG; Cabrol, MP; Chevret, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Kelaidi, C; Lamy, T; Le Bras, F; Sebert, M; Turlure, P; Vey, N; Visanica, S; Wattel, E, 2012) |
| "Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM)." | 3.78 | Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. ( Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C, 2012) |
| "Two pivotal, phase III, randomised, placebo-controlled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma." | 3.78 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D, 2012) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 3.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "Lenalidomide consistently induces transfusion independence and complete cytogenetic response in patients with myelodysplastic syndromes with 5q deletion." | 3.76 | Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. ( Aul, C; Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Kreipe, HH; Schlegelberger, B; Zimmermann, M, 2010) |
| "To obtain efficacy and safety data on lenalidomide treatment outside of clinical trials, we analyzed the clinical data of 114 patients with refractory or relapsed multiple myeloma treated with lenalidomide on a compassionate use basis." | 3.76 | Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. ( Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S, 2010) |
| "To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma." | 3.74 | Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. ( Bergsagel, PL; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR, 2007) |
| "Azotemia associated with the use of lenalidomide, a new and effective therapy for multiple myeloma, has not been reported in patients with multiple myeloma." | 3.74 | Azotemia associated with use of lenalidomide in plasma cell dyscrasias. ( Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V, 2008) |
| "To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide." | 3.73 | Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. ( Goldenberg, A; Lehrer, D; Liebes, L; Mandeli, J; Schwartz, JD; Schwartz, M; Sung, M; Volm, M, 2005) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 3.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine." | 3.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma." | 3.72 | Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Iturria, NL; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "After the second recurrence of spinal seeding in hemangioblastoma not associated to von-Hippel-Lindau disease, we treated an adult female patient with thalidomide 200 mg orally/day at night for longer than 1 year." | 3.72 | Stabilization of a progressive hemangioblastoma under treatment with thalidomide. ( Birner, P; Czech, T; Dieckmann, K; Fazeny-Dörner, B; Hainfellner, JA; Marosi, C; Piribauer, M; Prayer, D; Weinländer, G, 2004) |
| "Thalidomide-based regimens (TBR) are now widely used for the treatment of refractory multiple myeloma and have shown significant activity in newly diagnosed patients." | 3.72 | Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. ( Anagnostopoulos, A; Anagnostou, D; Dimopoulos, MA; Grigoraki, V; Hamilos, G; Zorzou, MP, 2004) |
| "Thalidomide has been shown to be effective in approximately 30% of patients with refractory or advanced multiple myeloma (MM)." | 3.72 | Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. ( Balleari, E; Falcone, A; Ghio, R; Musto, P, 2004) |
| "In our experience with thalidomide treatment for refractory multiple myeloma (MM), most patients with progressive disease (PD) did not show an increase in M-protein despite the tumor burden of myeloma cells." | 3.72 | Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Kuroda, Y; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2004) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 3.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 3.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "One patient developed autoimmune hemolytic anemia and another grade 4 thrombocytopenia." | 2.87 | Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. ( Adamson, L; Eriksson, I; Gentilcore, G; Hansson, L; Heimersson, K; Mellstedt, H; Mozaffari, F; Mulder, TA; Näsman-Glaser, B; Österborg, A; Palma, M; Ryblom, H; Svensson, A, 2018) |
| "Lenalidomide has immunomodulatory and anti-angiogenic effects and showed moderate anti-tumour efficacy in patients with." | 2.84 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ, 2017) |
| "Lenalidomide is an efficacious maintenance therapy reducing the relative risk of progression in first-line patients with chronic lymphocytic leukaemia who do not achieve minimal residual disease negative disease state following chemoimmunotherapy approaches." | 2.84 | Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. ( Al-Sawaf, O; Aldaoud, A; Bahlo, J; Bosch, F; Böttcher, S; Döhner, H; Dörfel, S; Eichhorst, B; Fink, AM; Fischer, K; Ghia, P; Hallek, M; Hebart, H; Jentsch-Ullrich, K; Kater, AP; Kneba, M; Kreuzer, KA; Nösslinger, T; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; Wendtner, CM, 2017) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 2.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM)." | 2.82 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. ( Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB, 2016) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 2.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Thalidomide and TACE were commonly associated with nonhematologic side effects, with fatigue and constipation being prominent." | 2.79 | Chronic thalidomide and chemoembolization for hepatocellular carcinoma. ( Christos, PJ; Goldenberg, AS; Hochster, HS; Muggia, FM; Ng, J; Sparano, J; Sung, MW; Wu, J, 2014) |
| "Patients received oral lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months, until disease progression or development of unacceptable adverse events (AEs)." | 2.78 | A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. ( Bosly, A; Coiffier, B; Delarue, R; Fitoussi, O; Gabarre, J; Glaisner, S; Haioun, C; Li, J; Lister, J; Morschhauser, F; Quach, H; Thieblemont, C, 2013) |
| "The lenalidomide dose was 25 mg/day, and was adjusted according to baseline renal function." | 2.78 | A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ( Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB, 2013) |
| "For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop." | 2.78 | Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. ( Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF, 2013) |
| "Lenalidomide is an immunomodulatory agent with proven tumoricidal and antiproliferative activity in MCL." | 2.78 | Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. ( Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L, 2013) |
| "Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM)." | 2.78 | A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. ( Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE, 2013) |
| "Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13." | 2.77 | Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. ( Antonarakis, ES; Carducci, M; Drake, CG; Eisenberger, MA; Keizman, D; McNeel, DG; Smith, HA; Thoburn, CJ; Zabransky, DJ; Zahurak, M, 2012) |
| "Thalidomide was continued until the time of disease progression or documented severe toxicity." | 2.77 | Low-dose thalidomide in patients with metastatic renal cell carcinoma. ( Hashmi, A; Masood, R; Naimatullah, N; Qayyum, A; Tunio, MA, 2012) |
| "Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study." | 2.76 | A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. ( Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M, 2011) |
| "Lenalidomide has acceptable toxicity and is associated with long-term disease stabilization and PSA declines." | 2.75 | Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. ( Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M, 2010) |
| "NP regimen combined with thalidomide can significantly prolong the median time to tumor progression in patients with advanced NSCLC." | 2.74 | [Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer]. ( Gu, AQ; Han, BH; Qi, DJ; Shen, J; Song, YY; Xin, Y; Xiong, LW; Zhang, XY, 2009) |
| "Disease progression was observed in 14 (45%) patients." | 2.73 | Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. ( Amato, RJ; Malya, R; Rawat, A, 2008) |
| "Lenalidomide is a safe and effective therapy for refractory metastatic RCC." | 2.73 | Lenalidomide therapy for metastatic renal cell carcinoma. ( Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S, 2008) |
| "Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy." | 2.73 | Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Hollmig, K; Jenkins, B; Kumar, NS; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Srivastava, G; Szymonifka, J; van Rhee, F; Yaccoby, S; Zeldis, JB, 2008) |
| " Food and Drug Administration (FDA) on June 29, 2006, for use in combination with dexamethasone in patients with multiple myeloma (MM) who have received at least one prior therapy." | 2.73 | Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. ( Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G, 2008) |
| "Thalidomide has been shown to inhibit production of TNF-alpha." | 2.73 | Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. ( Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Piccirillo, N; Sica, S; Tarnani, M, 2007) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| "Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma." | 2.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Patients with proven metastatic renal cell carcinoma were examined prospectively with functional CT." | 2.73 | CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. ( Charnsangavej, C; Daliani, D; Faria, SC; Hess, KR; Ng, CS; Phongkitkarun, S; Szejnfeld, J, 2007) |
| "Since thyroid carcinomas are hypervascular and thalidomide is antiangiogenic, we assessed thalidomide's tumoristatic effects and toxicity in a phase II trial." | 2.73 | Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. ( Ain, KB; Lee, C; Williams, KD, 2007) |
| "The treatment with thalidomide was continued as maintenance for up to 2 years." | 2.73 | Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. ( Buchler, T; Ellis, P; Hackshaw, A; James, L; Lee, SM; Snee, M, 2008) |
| " The differences in pharmacokinetic parameters between normal renal function and mild renal impairment were minor to modest (11%-32%)." | 2.73 | Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. ( Chen, N; Knight, R; Kong, L; Kumar, G; Laskin, OL; Lau, H; Zeldis, JB, 2007) |
| " The recommended phase II dosing schedule is thalidomide 100 mg twice daily with docetaxel 25 mg/m(2)/week." | 2.73 | Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. ( Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL, 2008) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 2.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Thalidomide in combination with IL-2 is tolerable and can produce durable, active responses in patients with MRCC." | 2.72 | Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. ( Amato, RJ; Morgan, M; Rawat, A, 2006) |
| "Thalidomide was started at 100 mg/d orally (PO) and escalated by 100 mg/d every 2 weeks to the maximum dose of 400 mg/d." | 2.72 | Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. ( A'Hern, R; Beirne, DA; Eisen, T; Gore, ME; Hancock, BW; James, MG; Lee, CP; Mak, I; Patel, PM; Pyle, L; Selby, PJ; Steeds, S, 2006) |
| "Thalidomide has shown promise for the treatment of patients with myelodysplastic syndrome." | 2.72 | Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. ( Alberts, SR; Colon-Otero, G; Geyer, SM; Hoering, A; Li, CY; Menke, DM; Moreno-Aspitia, A; Niedringhaus, RD; Tefferi, A; Vukov, A, 2006) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 2.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 2.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| "Thalidomide was started at 100 mg/day for 2 weeks and then escalated 200 mg every 2 weeks to 1000 mg or until grade 3-4 toxicity developed." | 2.71 | Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. ( Brinkley, W; Clark, PE; Das, S; Hall, MC; Lovato, JF; Miller, A; Patton, SE; Ridenhour, KP; Stindt, D; Torti, FM, 2004) |
| "The treatment of patients with hepatocellular carcinoma (HCC) presents a major challenge, because associated cirrhosis limits the choice of chemotherapeutic agents." | 2.71 | Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. ( Abbruzzese, JL; Brown, TD; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Zeldis, JB, 2005) |
| "Metastatic renal cell cancer is one of the immuno-sensitive tumors." | 2.71 | Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. ( Bex, A; Boogerd, W; de Gast, GC; Dewit, L; Haanen, JB; Kerst, JM; Mallo, H; Teertstra, HJ, 2005) |
| "Treatment continued until disease progression or unacceptable toxicity were encountered." | 2.70 | The treatment of advanced renal cell cancer with high-dose oral thalidomide. ( Ahern, R; Benson, C; Bridle, H; Eisen, T; Gore, ME; Mak, I; Pyle, L; Sapunar, F; Smalley, K; Stebbing, J, 2001) |
| "Thalidomide was initiated at 200 mg;3>daily and increased to a target dose of 1000 mg daily." | 2.70 | Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. ( Abbruzzese, JL; El-Naggar, AK; Ginsberg, LE; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Lawhorn, KN; Myers, JN; Pluda, JM; Roach, JS; Shin, DM; Steinhaus, GD; Teddy, S; Thall, PF; Tseng, JE; Wang, X; Zentgraf, RE, 2001) |
| "Thalidomide is a well-tolerated drug that may have some activity in the treatment of recurrent glioblastoma." | 2.70 | Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. ( Bell, DR; Biggs, M; Boyle, FM; Cook, R; Levi, JA; Little, N; Marx, GM; McCowatt, S; Pavlakis, N; Wheeler, HR, 2001) |
| "Oral thalidomide was tolerated in this population at doses up to 1,000 mg/d for as long as 12 months and was found to induce clinically meaningful anti-KS responses in a sizable subset of the patients." | 2.69 | Activity of thalidomide in AIDS-related Kaposi's sarcoma. ( Feigal, E; Figg, WD; Goedert, JJ; Little, RF; Marshall, V; Newcomb, FM; Pluda, JM; Steinberg, SM; Tosato, G; Welles, L; Whitby, D; Wyvill, KM; Yarchoan, R, 2000) |
| "Lenalidomide does not only promotes tumor apoptosis, but also stimulates T and NK cells, thereby facilitating NK-mediated tumor recognition and killing." | 2.55 | Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. ( Berchem, G; Giuliani, M; Janji, B, 2017) |
| "Multiple myeloma is a plasma cell skeletal malignancy." | 2.53 | Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. ( Hazlehurst, L; Lynch, CC; Shay, G, 2016) |
| "Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options." | 2.53 | Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. ( Aldredge, L; Armstrong, AW; Yamauchi, PS, 2016) |
| "Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder and bridges monoclonal gammopathy of undetermined significance to multiple myeloma (MM), based on higher levels of circulating monoclonal immunoglobulin and bone marrow plasmocytosis without end-organ damage." | 2.53 | The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. ( Beguin, Y; Caers, J; Decaux, O; Dimopoulos, M; Engelhardt, M; Fernández de Larrea, C; Heusschen, R; Jurczyszyn, A; Kastritis, E; Leleu, X; Ludwig, H; Mateos, MV; Minnema, M; Palumbo, A; Wäsch, R; Zojer, N, 2016) |
| "Smoldering multiple myeloma (SMM) is a precursor disease of multiple myeloma (MM) with an average annual risk of progression to MM of 10%." | 2.52 | [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. ( Jurczyszyn, A; Olszewska-Szopa, M; Skotnicki, AB, 2015) |
| "Waldenström's macroglobulinemia is a rare B-cell malignancy defined by medullar infiltration by clonal lymphoplasmocytic cells and monoclonal IgM secretion." | 2.50 | Current and future therapeutic approach for Waldenström's macroglobulinemia. ( Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L, 2014) |
| "Lenalidomide also has meaningful clinical activity in lower-risk patients without deletion 5q." | 2.46 | Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? ( Komrokji, RS; Lancet, JE; List, AF, 2010) |
| "Although no cure exists for multiple myeloma, current treatments, such as oral melphalan and prednisone, can slow disease progression and prolong overall survival." | 2.44 | Clinical updates and nursing considerations for patients with multiple myeloma. ( Faiman, B, 2007) |
| "When thalidomide was added to standard, non-transplantation myeloma therapy, overall survival (OS) improved (HR 0." | 2.44 | A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. ( Haynes, AE; Herst, JA; Hicks, LK; Imrie, K; Meyer, RM; Reece, DE; Walker, IR, 2008) |
| " As a result of adverse effects, salvage therapy had to be discontinued or reduced in 14 patients (26%)." | 2.42 | Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center. ( Berlanga, J; Büchler, T; Encuentra, M; Ferra, C; Gallardo, D; Grañena, A; Hermosilla, M; Sarra, J, 2003) |
| "Although multiple myeloma (MM) is sensitive to chemotherapy and radiation therapy, long-term disease-free survival is rare, and MM remains incurable despite conventional and high-dose therapies." | 2.42 | Targeting multiple myeloma cells and their bone marrow microenvironment. ( Cardinale, G; Gervasi, F; Pagnucco, G, 2004) |
| "Relapsing patients with multiple myeloma show a response rate higher than 50% with the resumption of the initial chemotherapy." | 2.41 | Treatment approaches for relapsing and refractory multiple myeloma. ( Bladé, J; Esteve, J, 2000) |
| "Marketed drugs for Parkinson's disease (PD) treat disease motor symptoms but are ineffective in stopping or slowing disease progression." | 1.72 | Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. ( Bernardini, R; Burgaletto, C; Cantarella, G; Carboni, E; Cardia, MC; Carta, AR; Casu, MA; Coroneo, V; De Simone, A; Ena, A; Etzi, M; Fusco, G; Greig, NH; Lai, F; Palmas, MF; Picci, L; Pisanu, A; Scerba, MT; Tweedie, D, 2022) |
| "Pomalidomide exposure was not associated with higher probabilities of treatment-emergent adverse events or pomalidomide dose interruptions during Cycle 1." | 1.62 | Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. ( Benettaib, B; Kassir, N; Li, Y; Ogasawara, K; Palmisano, M; Wang, X; Zhou, S, 2021) |
| "Thalidomide is a drug that has been reported to inhibit angiogenesis and reduce VEGF production by downregulating VEGF expression." | 1.48 | Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice. ( Cai, DZ; Fang, H; Li, L; Song, JL, 2018) |
| "Progression to multiple myeloma is the most common pattern of relapse." | 1.46 | Metachronous solitary plasmacytoma. ( Khosa, R; Nangia, S; Seth, S, 2017) |
| "Lenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy." | 1.46 | Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). ( Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M, 2017) |
| "We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression." | 1.46 | Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. ( Bernardini, A; Boccadoro, M; Caravita, T; Conticello, C; Drandi, D; Ferrero, S; Gambella, M; Gay, F; Genuardi, M; Gilestro, M; Liberati, AM; Muccio, VE; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Pautasso, C; Pescosta, N; Petrucci, MT; Rocci, A; Saraci, E, 2017) |
| "Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways." | 1.43 | A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. ( Cannizzaro, MV; Caposiena, D; Chimenti, S; Chiricozzi, A; Garofalo, V; Saraceno, R, 2016) |
| "Autoimmune diseases are prevalent among MDS patients." | 1.43 | Autoimmune diseases and myelodysplastic syndromes. ( Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L, 2016) |
| "Lenalidomide was not associated with AML transformation in the cohort analysis (HR = 0." | 1.43 | Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. ( Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q, 2016) |
| "Lenalidomide was discontinued after 10 days due to exacerbation of renal dysfunction." | 1.42 | Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide. ( Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y, 2015) |
| "Secondary monoclonal gammopathy of undetermined significance (MGUS) is a special phenomenon that occurs during the treatment of multiple myeloma (MM)." | 1.40 | Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. ( An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D, 2014) |
| "Four patients died due to disease progression and 17 were found to have progressed after ASCT (the median progression-free survival after ASCT was 19." | 1.40 | Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. ( Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST, 2014) |
| "Cerebral aneurysms were induced through hypertension and a single stereotactic injection of elastase into the basal cistern in mice." | 1.40 | Critical role of TNF-α in cerebral aneurysm formation and progression to rupture. ( Chalouhi, N; Dumont, AS; Gonzalez, LF; Greig, NH; Hasan, DM; Jabbour, PM; Owens, GK; Rosenwasser, RH; Shimada, K; Starke, RM; Tjoumakaris, SI; Wada, K, 2014) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Thalidomide was marketed for the treatment of morning sickness and resulted in foetal death and physical deformities." | 1.39 | Late-onset neurological symptoms in thalidomide-exposed subjects: a study of an Australasian cohort. ( Burke, D; Jankelowitz, SK; Spies, JM, 2013) |
| "We report on a case of Waldenström's macroglobulinemia (WM) treated with splenic re-irradiation." | 1.38 | Splenic re-irradiation for waldenstrőm's macroglobulinemia. ( Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J, 2012) |
| "Lenalidomide therapy was initiated, and the patient's skin condition improved after 6 weeks of treatment; however, his MDS progressed to acute myeloid leukemia, and he died shortly thereafter." | 1.37 | Myelodysplastic syndrome presenting as generalized granulomatous dermatitis. ( Balin, SJ; Kurtin, PJ; Letendre, L; Pittelkow, MR; Wetter, DA, 2011) |
| "Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included." | 1.37 | Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. ( Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D, 2011) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly." | 1.36 | Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). ( Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S, 2010) |
| "Lenalidomide-based treatment is effective across the spectrum of MM disease phases, allowing for the long-term management of myeloma." | 1.36 | Lenalidomide: an update on evidence from clinical trials. ( Dimopoulos, MA; Terpos, E, 2010) |
| "A report into recurrent prostate cancer by Figg et al." | 1.35 | Prostate cancer: thalidomide for prostate cancer: is there progress? ( Efstathiou, E; Logothetis, CJ, 2009) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | 1.34 | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "Thalidomide has been used as a salvage regimen at the study institution since 1999." | 1.34 | Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. ( Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Caravita, T; Cavallo, F; Falco, P; Gay, F; Palumbo, A, 2007) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 1.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects." | 1.33 | Thalidomide neuropathy in childhood. ( Chaitow, J; Darras, BT; Fleming, FJ; Jones, HR; Ryan, MM; Vytopil, M, 2005) |
| "These cases of unconventional disease recurrence are likely to be seen due to sub-clinical seeding of tumour cells suggestive of the presence of an extramedullary (EM) clone of plasma cells with a high degree of chemoresistance." | 1.33 | Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. ( Apperley, JF; Basu, S; Milne, AE; Rahemtulla, A; Rezvani, K; Rose, PE; Samson, D; Scott, GL; Terpos, E, 2005) |
| "Thalidomide was orally administrated 30 mg/kg/day and glucantime was administrated intraperitoneally (200 mg/kg/day)." | 1.33 | Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice. ( Abdi, K; Darabi, M; Ghareghozloo, B; Kariminia, A; Solgi, G, 2006) |
| "Oral thalidomide was started at 200 mg/d and escalated after two days to 400 mg/d at week 0." | 1.33 | [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. ( Hegele, A; Heidenreich, A; Hofmann, R; Olbert, P; Schrader, AJ; Varga, Z, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.63) | 18.2507 |
| 2000's | 127 (40.19) | 29.6817 |
| 2010's | 178 (56.33) | 24.3611 |
| 2020's | 9 (2.85) | 2.80 |
| Authors | Studies |
|---|---|
| Palmas, MF | 1 |
| Ena, A | 1 |
| Burgaletto, C | 1 |
| Casu, MA | 1 |
| Cantarella, G | 1 |
| Carboni, E | 1 |
| Etzi, M | 1 |
| De Simone, A | 1 |
| Fusco, G | 1 |
| Cardia, MC | 1 |
| Lai, F | 1 |
| Picci, L | 1 |
| Tweedie, D | 1 |
| Scerba, MT | 1 |
| Coroneo, V | 1 |
| Bernardini, R | 1 |
| Greig, NH | 2 |
| Pisanu, A | 1 |
| Carta, AR | 1 |
| Certan, M | 1 |
| Garcia Garrido, HM | 1 |
| Wong, G | 1 |
| Heijmans, J | 1 |
| Grobusch, MP | 1 |
| Goorhuis, A | 1 |
| Hawley, JE | 1 |
| Pan, S | 1 |
| Figg, WD | 4 |
| Lopez-Bujanda, ZA | 1 |
| Strope, JD | 1 |
| Aggen, DH | 1 |
| Dallos, MC | 1 |
| Lim, EA | 1 |
| Stein, MN | 1 |
| Hu, J | 1 |
| Drake, CG | 2 |
| Man, S | 1 |
| Ji, X | 1 |
| Wang, Y | 2 |
| Ma, Y | 1 |
| Hu, Z | 1 |
| Zhu, J | 1 |
| Zhang, J | 2 |
| Huang, F | 1 |
| Susek, KH | 1 |
| Gran, C | 1 |
| Ljunggren, HG | 1 |
| Alici, E | 1 |
| Nahi, H | 1 |
| Belch, A | 4 |
| Bahlis, N | 1 |
| White, D | 1 |
| Cheung, M | 1 |
| Chen, C | 3 |
| Shustik, C | 2 |
| Song, K | 2 |
| Tosikyan, A | 2 |
| Dispenzieri, A | 11 |
| Anderson, K | 2 |
| Brown, D | 1 |
| Robinson, S | 1 |
| Srinivasan, S | 1 |
| Facon, T | 9 |
| Liu, Y | 2 |
| Tang, CH | 1 |
| Qiu, H | 1 |
| Siggins, S | 1 |
| Hou, HA | 1 |
| Ogasawara, K | 1 |
| Kassir, N | 1 |
| Wang, X | 2 |
| Benettaib, B | 2 |
| Zhou, S | 1 |
| Palmisano, M | 1 |
| Li, Y | 1 |
| Lurain, K | 1 |
| Ramaswami, R | 1 |
| Mangusan, R | 1 |
| Widell, A | 1 |
| Ekwede, I | 1 |
| George, J | 1 |
| Ambinder, R | 1 |
| Cheever, M | 1 |
| Gulley, JL | 1 |
| Goncalves, PH | 1 |
| Wang, HW | 1 |
| Uldrick, TS | 1 |
| Yarchoan, R | 2 |
| Park, S | 2 |
| Hamel, JF | 1 |
| Toma, A | 2 |
| Kelaidi, C | 2 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 2 |
| Sekeres, MA | 5 |
| Balleari, E | 3 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 3 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 2 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 2 |
| Calabuig, M | 2 |
| Guerci-Bresler, A | 3 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 2 |
| Rose, C | 1 |
| Vey, N | 3 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 3 |
| Sanz, GF | 2 |
| Dreyfus, F | 2 |
| Fenaux, P | 8 |
| Holmberg, LA | 1 |
| Becker, PS | 2 |
| Bensinger, W | 5 |
| Pramanik, R | 1 |
| Agarwala, S | 1 |
| Gupta, YK | 1 |
| Thulkar, S | 1 |
| Vishnubhatla, S | 1 |
| Batra, A | 1 |
| Dhawan, D | 1 |
| Bakhshi, S | 1 |
| da Silva-Coelho, P | 1 |
| Kroeze, LI | 1 |
| Yoshida, K | 1 |
| Koorenhof-Scheele, TN | 1 |
| Knops, R | 1 |
| van de Locht, LT | 1 |
| de Graaf, AO | 1 |
| Massop, M | 1 |
| Sandmann, S | 1 |
| Dugas, M | 1 |
| Stevens-Kroef, MJ | 1 |
| Cermak, J | 1 |
| Shiraishi, Y | 1 |
| Chiba, K | 1 |
| Tanaka, H | 1 |
| Miyano, S | 1 |
| de Witte, T | 1 |
| Blijlevens, NMA | 1 |
| Muus, P | 3 |
| Huls, G | 2 |
| van der Reijden, BA | 1 |
| Ogawa, S | 1 |
| Jansen, JH | 1 |
| Bagot, M | 1 |
| Hasan, B | 1 |
| Whittaker, S | 1 |
| Beylot-Barry, M | 1 |
| Knobler, R | 1 |
| Shah, E | 1 |
| Marreaud, S | 1 |
| Morris, S | 1 |
| Dalle, S | 1 |
| Servitje, O | 1 |
| Cowan, R | 1 |
| Väkevä, L | 1 |
| Chaby, G | 1 |
| Jonak, C | 1 |
| Fox, CP | 1 |
| Ritchie, D | 2 |
| Vermeer, MH | 1 |
| Stadler, R | 1 |
| Romero, PLO | 1 |
| Scarisbrick, J | 1 |
| Quaglino, P | 1 |
| Tian, C | 1 |
| Yang, H | 1 |
| Zhu, L | 1 |
| Zhang, Q | 1 |
| Cao, Z | 1 |
| Zhang, Y | 1 |
| Giagounidis, A | 6 |
| Selleslag, D | 2 |
| Mittelman, M | 2 |
| Nimer, SD | 2 |
| Hellström-Lindberg, E | 7 |
| Powell, BL | 1 |
| Deeg, HJ | 1 |
| Del Cañizo, C | 4 |
| Greenberg, PL | 1 |
| Shammo, JM | 2 |
| Skikne, B | 2 |
| Yu, X | 2 |
| List, AF | 5 |
| Wang, GM | 1 |
| Yang, GZ | 1 |
| Huang, ZX | 1 |
| Zhong, YP | 1 |
| Jin, FY | 1 |
| Liao, AJ | 1 |
| Wang, XM | 1 |
| Fu, ZZ | 1 |
| Liu, H | 1 |
| Li, XL | 1 |
| Zhou, JF | 1 |
| Zhang, X | 1 |
| Hu, Y | 1 |
| Meng, FY | 1 |
| Huang, XJ | 1 |
| Chen, WM | 2 |
| Lu, J | 3 |
| McCarthy, PL | 2 |
| Holstein, SA | 1 |
| Petrucci, MT | 6 |
| Richardson, PG | 3 |
| Hulin, C | 5 |
| Tosi, P | 2 |
| Bringhen, S | 3 |
| Musto, P | 4 |
| Anderson, KC | 7 |
| Caillot, D | 1 |
| Gay, F | 5 |
| Moreau, P | 5 |
| Marit, G | 1 |
| Jung, SH | 2 |
| Yu, Z | 5 |
| Winograd, B | 1 |
| Knight, RD | 6 |
| Palumbo, A | 11 |
| Attal, M | 2 |
| Shao, YY | 2 |
| Chen, BB | 1 |
| Ou, DL | 1 |
| Lin, ZZ | 2 |
| Hsu, CH | 2 |
| Wang, MJ | 1 |
| Cheng, AL | 2 |
| Hsu, C | 2 |
| Persons, B | 1 |
| Chawla, R | 1 |
| Carter, J | 1 |
| Bhatnagar, V | 1 |
| Gormley, NJ | 1 |
| Luo, L | 1 |
| Shen, YL | 1 |
| Sridhara, R | 2 |
| Subramaniam, S | 1 |
| Shen, G | 1 |
| Ma, L | 1 |
| Shord, S | 1 |
| Goldberg, KB | 1 |
| Farrell, AT | 1 |
| McKee, AE | 1 |
| Pazdur, R | 2 |
| Fink, AM | 1 |
| Bahlo, J | 1 |
| Robrecht, S | 1 |
| Al-Sawaf, O | 1 |
| Aldaoud, A | 1 |
| Hebart, H | 1 |
| Jentsch-Ullrich, K | 1 |
| Dörfel, S | 1 |
| Fischer, K | 1 |
| Wendtner, CM | 1 |
| Nösslinger, T | 2 |
| Ghia, P | 1 |
| Bosch, F | 1 |
| Kater, AP | 1 |
| Döhner, H | 1 |
| Kneba, M | 1 |
| Kreuzer, KA | 1 |
| Tausch, E | 1 |
| Stilgenbauer, S | 1 |
| Ritgen, M | 1 |
| Böttcher, S | 1 |
| Eichhorst, B | 1 |
| Hallek, M | 1 |
| Tzogani, K | 1 |
| Camarero Jiménez, J | 1 |
| Garcia, I | 1 |
| Sancho-López, A | 2 |
| Martin, M | 1 |
| Moreau, A | 1 |
| Demolis, P | 1 |
| Salmonson, T | 2 |
| Bergh, J | 1 |
| Laane, E | 2 |
| Ludwig, H | 3 |
| Gisselbrecht, C | 2 |
| Pignatti, F | 2 |
| Khosa, R | 1 |
| Seth, S | 1 |
| Nangia, S | 1 |
| Wang, M | 6 |
| Schuster, SJ | 1 |
| Phillips, T | 1 |
| Lossos, IS | 2 |
| Goy, A | 2 |
| Rule, S | 1 |
| Hamadani, M | 1 |
| Ghosh, N | 1 |
| Reeder, CB | 4 |
| Barnett, E | 1 |
| Bravo, MC | 1 |
| Martin, P | 1 |
| Shen, Z | 1 |
| Zhou, R | 1 |
| Liu, C | 1 |
| Zhan, W | 1 |
| Shao, Z | 1 |
| Liu, J | 1 |
| Zhang, F | 1 |
| Xu, L | 1 |
| Zhou, X | 2 |
| Qi, L | 1 |
| Bo, F | 1 |
| Ding, Y | 1 |
| Zhao, L | 1 |
| Gonzalez-McQuire, S | 1 |
| Yong, K | 2 |
| Leleu, H | 1 |
| Mennini, FS | 1 |
| Flinois, A | 1 |
| Gazzola, C | 1 |
| Schoen, P | 1 |
| Campioni, M | 1 |
| DeCosta, L | 1 |
| Fink, L | 1 |
| Arcioni, F | 1 |
| Roncadori, A | 1 |
| Di Battista, V | 1 |
| Tura, S | 1 |
| Covezzoli, A | 1 |
| Cundari, S | 1 |
| Mecucci, C | 1 |
| Palma, M | 1 |
| Hansson, L | 1 |
| Mulder, TA | 1 |
| Adamson, L | 1 |
| Näsman-Glaser, B | 1 |
| Eriksson, I | 1 |
| Heimersson, K | 1 |
| Ryblom, H | 1 |
| Mozaffari, F | 1 |
| Svensson, A | 1 |
| Gentilcore, G | 1 |
| Österborg, A | 1 |
| Mellstedt, H | 1 |
| Song, JL | 1 |
| Li, L | 2 |
| Fang, H | 1 |
| Cai, DZ | 1 |
| Gourd, E | 1 |
| Vertolli, U | 1 |
| Berno, T | 1 |
| Riva, M | 1 |
| Adami, F | 1 |
| Angelini, A | 1 |
| Calò, LA | 1 |
| de Assis Pereira Hansen, C | 1 |
| Filho, JS | 1 |
| de Mattos Nascimento, M | 1 |
| Alves, FA | 1 |
| Neotti, T | 1 |
| D Almeida Costa, F | 1 |
| Oliva, EN | 1 |
| Latagliata, R | 1 |
| Laganà, C | 1 |
| Breccia, M | 1 |
| Galimberti, S | 1 |
| Morabito, F | 3 |
| Poloni, A | 2 |
| Cortelezzi, A | 1 |
| Palumbo, G | 1 |
| Sanpaolo, G | 2 |
| Volpe, A | 1 |
| Specchia, G | 1 |
| Finelli, C | 1 |
| D'Errigo, MG | 1 |
| Rodà, F | 1 |
| Alati, C | 1 |
| Alimena, G | 1 |
| Nobile, F | 1 |
| Aloe Spiriti, MA | 1 |
| Niesvizky, R | 4 |
| Martin, TG | 1 |
| Bensinger, WI | 2 |
| Alsina, M | 4 |
| Siegel, DS | 2 |
| Kunkel, LA | 1 |
| Wong, AF | 1 |
| Lee, S | 2 |
| Orlowski, RZ | 4 |
| Amraoui, K | 1 |
| Belhadj, K | 2 |
| Maître, B | 1 |
| Jannière-Nartey, C | 1 |
| Dupuis, J | 1 |
| Lechtzin, N | 1 |
| Hilliard, ME | 1 |
| Horton, MR | 1 |
| Fowler, N | 1 |
| Wagner-Bartak, N | 1 |
| Feng, L | 2 |
| Romaguera, J | 1 |
| Neelapu, SS | 1 |
| Hagemeister, F | 1 |
| Fanale, M | 1 |
| Oki, Y | 1 |
| Pro, B | 1 |
| Shah, J | 1 |
| Thomas, S | 1 |
| Younes, A | 1 |
| Hosing, C | 1 |
| Zhang, L | 4 |
| Newberry, KJ | 1 |
| Desai, M | 1 |
| Cheng, N | 1 |
| Badillo, M | 1 |
| Bejarano, M | 1 |
| Chen, Y | 1 |
| Young, KH | 1 |
| Champlin, R | 1 |
| Kwak, L | 1 |
| Fayad, L | 1 |
| Buikhuisen, WA | 1 |
| Burgers, JA | 1 |
| Vincent, AD | 1 |
| Korse, CM | 1 |
| van Klaveren, RJ | 1 |
| Schramel, FM | 1 |
| Pavlakis, N | 2 |
| Nowak, AK | 1 |
| Custers, FL | 1 |
| Schouwink, JH | 1 |
| Gans, SJ | 1 |
| Groen, HJ | 1 |
| Strankinga, WF | 1 |
| Baas, P | 1 |
| Mallo, M | 1 |
| Del Rey, M | 1 |
| Ibáñez, M | 1 |
| Calasanz, MJ | 1 |
| Arenillas, L | 1 |
| Larráyoz, MJ | 1 |
| Pedro, C | 2 |
| Jerez, A | 1 |
| Maciejewski, J | 1 |
| Costa, D | 1 |
| Nomdedeu, M | 1 |
| Diez-Campelo, M | 3 |
| Lumbreras, E | 1 |
| González-Martínez, T | 1 |
| Marugán, I | 1 |
| Such, E | 2 |
| Cervera, J | 1 |
| Cigudosa, JC | 1 |
| Alvarez, S | 1 |
| Florensa, L | 1 |
| Hernández, JM | 1 |
| Solé, F | 1 |
| Nagano, S | 1 |
| Mori, M | 1 |
| Kato, A | 1 |
| Ono, Y | 1 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 1 |
| Imai, H | 1 |
| Takahashi, T | 1 |
| Mangiacavalli, S | 1 |
| Pochintesta, L | 1 |
| Cocito, F | 2 |
| Pompa, A | 1 |
| Bernasconi, P | 1 |
| Cazzola, M | 2 |
| Corso, A | 3 |
| Morschhauser, F | 1 |
| Fitoussi, O | 1 |
| Haioun, C | 1 |
| Thieblemont, C | 1 |
| Quach, H | 3 |
| Delarue, R | 1 |
| Glaisner, S | 1 |
| Gabarre, J | 1 |
| Bosly, A | 1 |
| Lister, J | 1 |
| Li, J | 5 |
| Coiffier, B | 1 |
| Magarotto, V | 3 |
| Crippa, C | 2 |
| Pescosta, N | 3 |
| Guglielmelli, T | 1 |
| Cavallo, F | 2 |
| Pezzatti, S | 1 |
| Ferrari, S | 1 |
| Liberati, AM | 3 |
| Oliva, S | 3 |
| Patriarca, F | 3 |
| Offidani, M | 4 |
| Omedé, P | 3 |
| Montefusco, V | 1 |
| Giuliani, N | 1 |
| Passera, R | 2 |
| Pietrantuono, G | 1 |
| Boccadoro, M | 6 |
| Corradini, P | 2 |
| Hou, J | 1 |
| Du, X | 1 |
| Jin, J | 1 |
| Cai, Z | 1 |
| Chen, F | 1 |
| Zhou, DB | 2 |
| Yu, L | 1 |
| Ke, X | 1 |
| Li, X | 1 |
| Wu, D | 1 |
| Meng, F | 1 |
| Ai, H | 1 |
| Wortman-Vayn, H | 1 |
| Chen, N | 2 |
| Mei, J | 1 |
| Wang, J | 2 |
| Vose, JM | 1 |
| Habermann, TM | 1 |
| Czuczman, MS | 2 |
| Zinzani, PL | 1 |
| Tuscano, JM | 1 |
| Pietronigro, D | 1 |
| Witzig, TE | 10 |
| Brunet-Possenti, F | 1 |
| Hermine, O | 1 |
| Marinho, E | 1 |
| Crickx, B | 1 |
| Descamps, V | 1 |
| Mateos, MV | 5 |
| Hernández, MT | 3 |
| Giraldo, P | 1 |
| de la Rubia, J | 2 |
| de Arriba, F | 2 |
| López Corral, L | 1 |
| Rosiñol, L | 2 |
| Paiva, B | 2 |
| Palomera, L | 2 |
| Bargay, J | 3 |
| Oriol, A | 3 |
| Prosper, F | 1 |
| López, J | 1 |
| Olavarría, E | 1 |
| Quintana, N | 1 |
| García, JL | 1 |
| Bladé, J | 7 |
| Lahuerta, JJ | 3 |
| San Miguel, JF | 3 |
| Fouquet, G | 1 |
| Tardy, S | 1 |
| Demarquette, H | 1 |
| Bonnet, S | 1 |
| Gay, J | 1 |
| Debarri, H | 1 |
| Herbaux, C | 1 |
| Guidez, S | 1 |
| Michel, J | 1 |
| Perrot, A | 1 |
| Serrier, C | 1 |
| Miljkovic, D | 1 |
| Avet Loiseau, H | 1 |
| Leleu, X | 4 |
| Sinha, R | 1 |
| Williams, ME | 1 |
| Kalayoglu Besisik, S | 1 |
| Drach, J | 2 |
| Ramchandren, R | 1 |
| Cicero, S | 1 |
| Fu, T | 3 |
| Martin, T | 1 |
| Kavalerchik, E | 1 |
| Huang, M | 1 |
| Mufti, GJ | 3 |
| List, A | 3 |
| MacBeth, KJ | 1 |
| de Souza, CM | 1 |
| Araújo e Silva, AC | 1 |
| de Jesus Ferraciolli, C | 1 |
| Moreira, GV | 1 |
| Campos, LC | 1 |
| dos Reis, DC | 1 |
| Lopes, MT | 1 |
| Ferreira, MA | 1 |
| Andrade, SP | 1 |
| Cassali, GD | 1 |
| Bennett, JM | 1 |
| Nabhan, C | 1 |
| Patel, A | 1 |
| Villines, D | 1 |
| Tolzien, K | 1 |
| Kelby, SK | 1 |
| Lestingi, TM | 1 |
| Kourelis, TV | 1 |
| Kumar, SK | 3 |
| Srivastava, G | 2 |
| Gertz, MA | 10 |
| Lacy, MQ | 10 |
| Buadi, FK | 2 |
| Hayman, SR | 7 |
| Zeldenrust, SR | 5 |
| Leung, N | 1 |
| Kyle, RA | 8 |
| Russell, SJ | 6 |
| Dingli, D | 4 |
| Lust, JA | 10 |
| Lin, Y | 1 |
| Kapoor, P | 1 |
| Go, R | 1 |
| Rajkumar, SV | 13 |
| Zou, D | 1 |
| An, G | 1 |
| Zhu, G | 1 |
| Shi, L | 1 |
| Meng, H | 1 |
| Xu, Y | 1 |
| Sui, W | 1 |
| Deng, S | 1 |
| Zhan, F | 1 |
| Qiu, L | 2 |
| Rojas, SM | 1 |
| Luño, E | 2 |
| Cabrero, M | 1 |
| Nomdedeu, B | 2 |
| Cedena, T | 1 |
| Arrizabalaga, B | 2 |
| García, M | 1 |
| Cerveró, C | 2 |
| Collado, R | 1 |
| Azaceta, G | 2 |
| Ardanaz, MT | 1 |
| Muñoz, JA | 1 |
| Xicoy, B | 2 |
| Rodríguez, MJ | 1 |
| Morell, MJ | 1 |
| Simiele, A | 1 |
| Green, DJ | 1 |
| Burwick, N | 1 |
| Kuendgen, A | 2 |
| Cooper, K | 1 |
| Picot, J | 1 |
| Bryant, J | 1 |
| Clegg, A | 1 |
| Shen, P | 1 |
| Thomas, CR | 1 |
| Fenstermaker, J | 1 |
| Aklilu, M | 1 |
| McCoy, TP | 1 |
| Levine, EA | 1 |
| Kampschulte, M | 1 |
| Gunkel, I | 1 |
| Stieger, P | 1 |
| Sedding, DG | 1 |
| Brinkmann, A | 1 |
| Ritman, EL | 1 |
| Krombach, GA | 1 |
| Langheinrich, AC | 1 |
| Tohyama, K | 2 |
| Scott, LJ | 1 |
| Sánchez-García, J | 1 |
| Lorenzo, I | 1 |
| de Paz, R | 1 |
| Valcárcel, D | 1 |
| Brunet, S | 1 |
| Marco-Betes, V | 1 |
| García-Pintos, M | 1 |
| Osorio, S | 1 |
| Tormo, M | 1 |
| Bailén, A | 1 |
| Arilla, MJ | 1 |
| Falantes, J | 1 |
| Serrano-López, J | 1 |
| Chang, WJ | 1 |
| Kang, ES | 1 |
| Lee, ST | 1 |
| Kim, SH | 1 |
| Kim, DW | 2 |
| Kim, SJ | 1 |
| Kim, K | 3 |
| Starke, RM | 1 |
| Chalouhi, N | 1 |
| Jabbour, PM | 1 |
| Tjoumakaris, SI | 1 |
| Gonzalez, LF | 1 |
| Rosenwasser, RH | 1 |
| Wada, K | 1 |
| Shimada, K | 1 |
| Hasan, DM | 1 |
| Owens, GK | 1 |
| Dumont, AS | 1 |
| Souchet-Cömpain, L | 1 |
| Choquet, S | 1 |
| Leblond, V | 1 |
| Nguyen, S | 1 |
| Sanz, G | 1 |
| Platzbecker, U | 2 |
| te Boekhorst, P | 1 |
| Nilsson, L | 1 |
| Lübbert, M | 1 |
| Quesnel, B | 1 |
| Ganser, A | 1 |
| Bowen, D | 1 |
| Schlegelberger, B | 4 |
| Göhring, G | 4 |
| Schleiffenbaum, BE | 1 |
| Lendvai, N | 1 |
| Hilden, P | 1 |
| Devlin, S | 1 |
| Landau, H | 1 |
| Hassoun, H | 2 |
| Lesokhin, AM | 1 |
| Tsakos, I | 1 |
| Redling, K | 1 |
| Koehne, G | 1 |
| Chung, DJ | 1 |
| Schaffer, WL | 1 |
| Giralt, SA | 1 |
| Zago, M | 1 |
| Oehrlein, K | 1 |
| Rendl, C | 1 |
| Hahn-Ast, C | 1 |
| Kanz, L | 1 |
| Weisel, K | 2 |
| Sharman, JP | 1 |
| Chmielecki, J | 1 |
| Morosini, D | 1 |
| Palmer, GA | 1 |
| Ross, JS | 1 |
| Stephens, PJ | 1 |
| Stafl, J | 1 |
| Miller, VA | 1 |
| Ali, SM | 1 |
| Cheng, J | 1 |
| Talamo, G | 1 |
| Malysz, J | 1 |
| Ochmann, M | 1 |
| Lamy, T | 2 |
| Loughran, TP | 1 |
| Kumar, AK | 1 |
| Dakhil, C | 1 |
| Teeka Satyan, M | 1 |
| Haideri, N | 1 |
| Cozzani, E | 1 |
| Gasparini, G | 2 |
| Parodi, A | 1 |
| Hobeika, L | 1 |
| Self, SE | 1 |
| Velez, JC | 1 |
| Wu, J | 1 |
| Ng, J | 1 |
| Christos, PJ | 1 |
| Goldenberg, AS | 1 |
| Sparano, J | 1 |
| Sung, MW | 1 |
| Hochster, HS | 1 |
| Muggia, FM | 1 |
| Usmani, SZ | 2 |
| Lonial, S | 4 |
| Nozzoli, C | 1 |
| Staderini, M | 1 |
| Veltroni, A | 1 |
| Longo, G | 1 |
| Bacchiarri, F | 1 |
| Donnini, I | 1 |
| Guarrera, A | 1 |
| Bosi, A | 2 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Hanaizi, Z | 1 |
| Flores, B | 1 |
| Hemmings, R | 1 |
| Camarero, J | 1 |
| Arikian, SR | 1 |
| Milentijevic, D | 1 |
| Binder, G | 1 |
| Gibson, CJ | 2 |
| Hu, XH | 1 |
| Nagarwala, Y | 1 |
| Hussein, M | 5 |
| Corvino, FA | 1 |
| Surinach, A | 1 |
| Cerqui, E | 1 |
| Pelizzari, A | 1 |
| Schieppati, F | 1 |
| Borlenghi, E | 1 |
| Pagani, C | 1 |
| Bellotti, D | 1 |
| Lamorgese, C | 1 |
| Boiocchi, L | 1 |
| Sottini, A | 1 |
| Imberti, L | 1 |
| Rossi, G | 1 |
| Cibeira, MT | 2 |
| Granell, M | 1 |
| Fernández de Larrea, C | 2 |
| Saburi, M | 1 |
| Ohtsuka, E | 1 |
| Itani, K | 1 |
| Nagamatsu, K | 1 |
| Ikebe, T | 1 |
| Miyazaki, Y | 1 |
| Ogata, M | 1 |
| Saburi, Y | 1 |
| Dimopoulos, M | 4 |
| Song, KW | 1 |
| Schey, S | 1 |
| Sonneveld, P | 5 |
| Sternas, L | 1 |
| Amatya, R | 1 |
| Zaki, M | 1 |
| Jacques, C | 1 |
| San Miguel, J | 2 |
| Cohen, C | 1 |
| Royer, B | 2 |
| Javaugue, V | 1 |
| Szalat, R | 1 |
| El Karoui, K | 1 |
| Caulier, A | 1 |
| Knebelmann, B | 1 |
| Jaccard, A | 2 |
| Chevret, S | 2 |
| Touchard, G | 1 |
| Fermand, JP | 1 |
| Arnulf, B | 1 |
| Bridoux, F | 1 |
| Yamasaki, S | 1 |
| Kohno, K | 1 |
| Kadowaki, M | 1 |
| Takase, K | 1 |
| Okamura, S | 1 |
| Garcia-Manero, G | 1 |
| Leonard, JP | 1 |
| Johnson, J | 1 |
| Pitcher, BN | 1 |
| Bartlett, NL | 1 |
| Blum, KA | 1 |
| Czuczman, M | 1 |
| Giguere, JK | 1 |
| Cheson, BD | 1 |
| Aylı, M | 1 |
| Özcan, M | 1 |
| Cengiz Seval, G | 1 |
| Aschauer, G | 1 |
| Greil, R | 1 |
| Linkesch, W | 1 |
| Stauder, R | 1 |
| Burgstaller, S | 1 |
| Fiegl, M | 1 |
| Fridrik, M | 1 |
| Girschikofsky, M | 1 |
| Keil, F | 1 |
| Petzer, A | 1 |
| Shay, G | 1 |
| Hazlehurst, L | 1 |
| Lynch, CC | 1 |
| Bersani-Amado, LE | 1 |
| Dantas, JA | 1 |
| Damião, MJ | 1 |
| Rocha, BA | 1 |
| Besson, JC | 1 |
| Bastos, RL | 1 |
| Silva, LN | 1 |
| Bersani-Amado, CA | 1 |
| Cuman, RK | 1 |
| Bagratuni, T | 1 |
| Terpos, E | 3 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kalapanida, D | 1 |
| Gavriatopoulou, M | 1 |
| Migkou, M | 1 |
| Liacos, CI | 1 |
| Tasidou, A | 1 |
| Matsouka, C | 2 |
| Mparmparousi, D | 1 |
| Dimopoulos, MA | 9 |
| Kastritis, E | 3 |
| Conticello, C | 2 |
| Catalano, L | 1 |
| Siniscalchi, A | 1 |
| Pour, L | 2 |
| Carella, A | 1 |
| Malfitano, A | 1 |
| Petrò, D | 1 |
| Evangelista, A | 1 |
| Spada, S | 1 |
| Campbell, P | 1 |
| Ria, R | 2 |
| Pulini, S | 1 |
| Hajek, R | 5 |
| Spencer, A | 3 |
| Huang, XE | 1 |
| Yan, XC | 1 |
| Wang, L | 2 |
| Ji, ZQ | 1 |
| Liu, MY | 1 |
| Qian, T | 1 |
| Shen, HL | 1 |
| Gu, HG | 1 |
| Gu, M | 1 |
| Deng, LC | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Dębski, J | 1 |
| Butrym, A | 2 |
| Legieć, W | 1 |
| Hus, M | 1 |
| Dmoszyńska, A | 2 |
| Stella-Hołowiecka, B | 1 |
| Zaucha, JM | 1 |
| Januszczyk, J | 1 |
| Rymko, M | 1 |
| Torosian, T | 1 |
| Charliński, G | 1 |
| Lech-Marańda, E | 1 |
| Malenda, A | 1 |
| Jurczyszyn, A | 3 |
| Urbańska-Ryś, H | 1 |
| Druzd-Sitek, A | 1 |
| Błońska, D | 1 |
| Urbanowicz, A | 1 |
| Hołojda, J | 1 |
| Pogrzeba, J | 1 |
| Rzepecki, P | 1 |
| Hałka, J | 1 |
| Subocz, E | 1 |
| Becht, R | 1 |
| Zdziarska, B | 1 |
| Dytfeld, D | 1 |
| Nowicki, A | 1 |
| Bołkun, Ł | 1 |
| Kłoczko, J | 1 |
| Knopińska-Posłuszny, W | 1 |
| Zubkiewicz-Kucharska, A | 1 |
| Kuliczkowski, K | 1 |
| Duvic, M | 1 |
| Cheung, MC | 1 |
| Roussel, M | 1 |
| Liu, T | 3 |
| Gamberi, B | 1 |
| Kolb, B | 1 |
| Derigs, HG | 1 |
| Eom, H | 1 |
| Lenain, P | 1 |
| Van der Jagt, R | 1 |
| Rigaudeau, S | 1 |
| Dib, M | 1 |
| Hall, R | 1 |
| Jardel, H | 1 |
| Karlin, L | 1 |
| Schots, R | 1 |
| Leupin, N | 2 |
| Chen, G | 3 |
| Marek, J | 1 |
| Ervin-Haynes, A | 4 |
| Chiricozzi, A | 1 |
| Caposiena, D | 1 |
| Garofalo, V | 1 |
| Cannizzaro, MV | 1 |
| Chimenti, S | 1 |
| Saraceno, R | 1 |
| Armstrong, AW | 1 |
| Aldredge, L | 1 |
| Yamauchi, PS | 1 |
| Corchete, LA | 1 |
| Vidriales, MB | 1 |
| Puig, N | 1 |
| Maiso, P | 1 |
| Rodriguez, I | 1 |
| Alignani, D | 1 |
| Burgos, L | 1 |
| Sanchez, ML | 1 |
| Barcena, P | 1 |
| Echeveste, MA | 1 |
| García-Sanz, R | 1 |
| Ocio, EM | 1 |
| Gironella, M | 1 |
| Gonzalez, Y | 1 |
| Johnson, SK | 1 |
| Epstein, J | 2 |
| Barlogie, B | 5 |
| Orfao, A | 1 |
| Shah, JJ | 1 |
| Thomas, SK | 1 |
| Berkova, Z | 1 |
| Weber, DM | 3 |
| Qazilbash, MH | 1 |
| Champlin, RE | 1 |
| Mendoza, TR | 1 |
| Cleeland, C | 1 |
| Komrokji, RS | 3 |
| Kulasekararaj, A | 1 |
| Al Ali, NH | 2 |
| Kordasti, S | 1 |
| Bart-Smith, E | 1 |
| Craig, BM | 1 |
| Padron, E | 2 |
| Lancet, JE | 2 |
| Pinilla-Ibarz, J | 1 |
| Epling-Burnette, PK | 1 |
| Chang, JE | 1 |
| Havighurst, T | 1 |
| Eickhoff, J | 1 |
| Traynor, AM | 1 |
| Kirby-Slimp, R | 1 |
| Volk, LM | 1 |
| Werndli, J | 1 |
| Go, RS | 2 |
| Weiss, M | 1 |
| Blank, J | 1 |
| Kahl, BS | 1 |
| Suzuki, K | 1 |
| Shinagawa, A | 1 |
| Uchida, T | 1 |
| Taniwaki, M | 1 |
| Hirata, H | 1 |
| Ishizawa, K | 2 |
| Matsue, K | 1 |
| Ogawa, Y | 1 |
| Shimizu, T | 2 |
| Otsuka, M | 2 |
| Matsumoto, M | 1 |
| Iida, S | 1 |
| Terui, Y | 1 |
| Matsumura, I | 1 |
| Ikeda, T | 1 |
| Takezako, N | 1 |
| Ogaki, Y | 1 |
| Midorikawa, S | 2 |
| Houck, V | 2 |
| Chou, T | 1 |
| Caers, J | 1 |
| Heusschen, R | 1 |
| Zojer, N | 1 |
| Decaux, O | 1 |
| Minnema, M | 1 |
| Beguin, Y | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| Kurozumi, K | 1 |
| Ishida, J | 1 |
| Ichikawa, T | 1 |
| Date, I | 1 |
| Townsend, W | 1 |
| Johnson, RJ | 1 |
| Pottinger, BT | 1 |
| Counsell, N | 1 |
| Smith, P | 1 |
| Chadwick, H | 1 |
| Evans, K | 1 |
| Wickham, C | 1 |
| Rudin, CE | 1 |
| Olszewska-Szopa, M | 1 |
| Skotnicki, AB | 1 |
| Rollison, DE | 1 |
| Shain, KH | 1 |
| Lee, JH | 3 |
| Hampras, SS | 1 |
| Fulp, W | 1 |
| Fisher, K | 1 |
| Lancet, J | 1 |
| Xu, Q | 1 |
| Olesnyckyj, M | 6 |
| Kenvin, L | 2 |
| Knight, R | 7 |
| Dalton, W | 2 |
| Wang, C | 1 |
| Guan, YZ | 1 |
| Cai, QQ | 1 |
| Su, W | 1 |
| Pan, L | 1 |
| Xiang, B | 1 |
| Zhu, H | 1 |
| Wu, Y | 1 |
| Chen, M | 1 |
| Guan, P | 1 |
| Zou, X | 1 |
| Valencia, CA | 1 |
| Dong, B | 1 |
| Xie, L | 1 |
| Ma, H | 1 |
| Wang, F | 1 |
| Dong, T | 1 |
| Shuai, X | 1 |
| Niu, T | 1 |
| Dührsen, U | 1 |
| Rodon, P | 1 |
| Pégourié, B | 1 |
| Garderet, L | 1 |
| Hunter, H | 1 |
| Azais, I | 1 |
| Eek, R | 1 |
| Gisslinger, H | 2 |
| Macro, M | 1 |
| Dakhil, S | 1 |
| Goncalves, C | 1 |
| LeBlanc, R | 1 |
| Romeril, K | 1 |
| Doyen, C | 1 |
| Offner, F | 1 |
| Lee, SE | 1 |
| Lim, JY | 1 |
| Ryu, DB | 1 |
| Kim, TW | 1 |
| Yoon, JH | 1 |
| Cho, BS | 1 |
| Eom, KS | 1 |
| Kim, YJ | 1 |
| Kim, HJ | 2 |
| Cho, SG | 1 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Kim, M | 1 |
| Min, CK | 2 |
| Pozzi, S | 1 |
| Gentile, M | 1 |
| Sacchi, S | 1 |
| Marcheselli, R | 1 |
| Guarini, A | 1 |
| Minoia, C | 1 |
| Vincelli, I | 1 |
| Rivolti, E | 1 |
| Mele, G | 1 |
| Bari, A | 1 |
| Mazzone, C | 1 |
| Badiali, S | 1 |
| Marcheselli, L | 1 |
| Ishida, T | 1 |
| Fujiwara, H | 1 |
| Nosaka, K | 1 |
| Taira, N | 1 |
| Abe, Y | 1 |
| Imaizumi, Y | 1 |
| Moriuchi, Y | 1 |
| Jo, T | 1 |
| Tobinai, K | 1 |
| Tsukasaki, K | 1 |
| Ito, S | 1 |
| Yoshimitsu, M | 1 |
| Ogura, M | 1 |
| Ruiz, W | 1 |
| Ohtsu, T | 1 |
| Gambella, M | 1 |
| Gilestro, M | 1 |
| Muccio, VE | 1 |
| Drandi, D | 1 |
| Ferrero, S | 1 |
| Pautasso, C | 1 |
| Bernardini, A | 1 |
| Genuardi, M | 2 |
| Saraci, E | 1 |
| Caravita, T | 3 |
| Rocci, A | 1 |
| Popat, R | 1 |
| Brown, SR | 1 |
| Flanagan, L | 1 |
| Hall, A | 1 |
| Gregory, W | 1 |
| Kishore, B | 1 |
| Streetly, M | 1 |
| Oakervee, H | 1 |
| Cook, G | 1 |
| Low, E | 1 |
| Cavenagh, J | 1 |
| Scharenberg, C | 1 |
| Giai, V | 1 |
| Pellagatti, A | 2 |
| Saft, L | 2 |
| Dimitriou, M | 1 |
| Jansson, M | 1 |
| Jädersten, M | 3 |
| Grandien, A | 1 |
| Douagi, I | 1 |
| Neuberg, DS | 1 |
| LeBlanc, K | 1 |
| Boultwood, J | 2 |
| Karimi, M | 1 |
| Jacobsen, SE | 1 |
| Woll, PS | 1 |
| Tacchetti, P | 2 |
| Pezzi, A | 1 |
| Zamagni, E | 2 |
| Pantani, L | 2 |
| Rocchi, S | 1 |
| Zannetti, BA | 1 |
| Mancuso, K | 1 |
| Rizzello, I | 1 |
| Cavo, M | 2 |
| Raturi, R | 1 |
| Patel, AA | 1 |
| Carter, JD | 1 |
| Łacina, P | 1 |
| Rybka, J | 1 |
| Chaszczewska-Markowska, M | 1 |
| Mazur, G | 1 |
| Bogunia-Kubik, K | 1 |
| Huang, SY | 1 |
| Lee, JJ | 1 |
| Yoon, SS | 2 |
| Shen, ZX | 1 |
| Eom, HS | 1 |
| Lee, JO | 1 |
| Kwak, JY | 1 |
| Yiu, W | 1 |
| Boudreault, JS | 1 |
| Touzeau, C | 2 |
| Chen, CC | 1 |
| Parikh, K | 1 |
| Abouzaid, S | 1 |
| Purnomo, L | 1 |
| McGuiness, CB | 1 |
| Wade, RL | 1 |
| Prebet, T | 1 |
| Cluzeau, T | 1 |
| Al Ali, N | 1 |
| Sugrue, MM | 1 |
| Gore, SD | 1 |
| Stahl, M | 1 |
| Zeidan, AM | 1 |
| Fernyhough, L | 1 |
| Henderson, R | 1 |
| Corbett, G | 1 |
| Baker, B | 1 |
| Browett, P | 1 |
| Blacklock, H | 1 |
| Forsyth, C | 1 |
| Underhill, C | 1 |
| Cannell, P | 1 |
| Trotman, J | 1 |
| Neylon, A | 1 |
| Harrison, S | 2 |
| Link, E | 1 |
| Swern, A | 1 |
| Cowan, L | 1 |
| Miles Prince, H | 1 |
| Giuliani, M | 1 |
| Janji, B | 1 |
| Berchem, G | 1 |
| Amato, RJ | 3 |
| Malya, R | 1 |
| Rawat, A | 2 |
| Hernandez-McClain, J | 1 |
| Saxena, S | 1 |
| Khan, M | 1 |
| Vestermark, LW | 1 |
| Larsen, S | 1 |
| Lindeløv, B | 1 |
| Bastholt, L | 1 |
| Fadul, CE | 1 |
| Kingman, LS | 1 |
| Meyer, LP | 1 |
| Cole, BF | 1 |
| Eskey, CJ | 1 |
| Rhodes, CH | 1 |
| Roberts, DW | 1 |
| Newton, HB | 1 |
| Pipas, JM | 1 |
| van Rhee, F | 2 |
| Shaughnessy, JD | 1 |
| Yaccoby, S | 1 |
| Pineda-Roman, M | 2 |
| Hollmig, K | 1 |
| Alsayed, Y | 1 |
| Hoering, A | 2 |
| Szymonifka, J | 1 |
| Anaissie, E | 3 |
| Petty, N | 1 |
| Kumar, NS | 1 |
| Jenkins, B | 1 |
| Crowley, J | 2 |
| Zeldis, JB | 8 |
| Minnema, MC | 2 |
| van der Veer, MS | 1 |
| Aarts, T | 1 |
| Emmelot, M | 1 |
| Mutis, T | 1 |
| Lokhorst, HM | 2 |
| Kassam, A | 1 |
| Mandel, K | 1 |
| Hazarika, M | 1 |
| Rock, E | 1 |
| Williams, G | 1 |
| Dagher, R | 1 |
| Booth, B | 1 |
| Farrell, A | 1 |
| Justice, R | 1 |
| Avvisati, G | 1 |
| Knop, S | 1 |
| Gerecke, C | 1 |
| Liebisch, P | 2 |
| Topp, MS | 1 |
| Sezer, O | 1 |
| Vollmuth, C | 1 |
| Falk, K | 1 |
| Glasmacher, A | 3 |
| Maeder, U | 1 |
| Einsele, H | 1 |
| Bargou, RC | 1 |
| Mileshkin, L | 2 |
| Seymour, JF | 2 |
| Milner, A | 1 |
| Westerman, D | 1 |
| Prince, HM | 4 |
| Koopmans, GC | 1 |
| Deumens, R | 1 |
| Buss, A | 1 |
| Geoghegan, L | 1 |
| Myint, AM | 1 |
| Honig, WH | 1 |
| Kern, N | 1 |
| Joosten, EA | 1 |
| Noth, J | 1 |
| Brook, GA | 1 |
| Gorgun, G | 1 |
| Ramsay, AG | 1 |
| Holderried, TA | 1 |
| Zahrieh, D | 1 |
| Le Dieu, R | 1 |
| Liu, F | 1 |
| Quackenbush, J | 1 |
| Croce, CM | 1 |
| Gribben, JG | 1 |
| Stone, RM | 1 |
| Efstathiou, E | 1 |
| Logothetis, CJ | 2 |
| Richardson, P | 2 |
| Jagannath, S | 3 |
| Berenson, J | 1 |
| Singhal, S | 3 |
| Irwin, D | 2 |
| Williams, SF | 1 |
| Badros, AZ | 1 |
| Vescio, R | 1 |
| Zeldis, J | 2 |
| Gu, AQ | 1 |
| Han, BH | 1 |
| Zhang, XY | 1 |
| Shen, J | 1 |
| Qi, DJ | 1 |
| Xiong, LW | 1 |
| Xin, Y | 1 |
| Song, YY | 1 |
| Vogl, DT | 1 |
| Stadtmauer, EA | 3 |
| Schuster, MW | 1 |
| Harousseau, JL | 5 |
| Boral, A | 1 |
| Neuwirth, R | 1 |
| Laubach, JP | 1 |
| Wainscoat, JS | 1 |
| Porwit, A | 1 |
| Büsche, G | 2 |
| Kreipe, HH | 1 |
| Zimmermann, M | 1 |
| Aul, C | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Eisen, T | 3 |
| Trefzer, U | 1 |
| Hamilton, A | 1 |
| Hersey, P | 1 |
| Millward, M | 1 |
| Jungnelius, JU | 1 |
| Glaspy, J | 1 |
| Krejci, M | 1 |
| Scudla, V | 1 |
| Tothova, E | 1 |
| Schutzova, M | 1 |
| Koza, V | 1 |
| Adam, Z | 1 |
| Krivanova, A | 1 |
| Buchler, T | 3 |
| Sandecka, V | 1 |
| Kralova, D | 1 |
| Zahradova, L | 2 |
| Vorlicek, J | 1 |
| Mayer, J | 1 |
| Kneppers, E | 1 |
| Eeltink, CM | 1 |
| Kersten, MJ | 1 |
| Koedam, J | 1 |
| van Oers, MH | 1 |
| Raymakers, RA | 1 |
| Schaafsma, MR | 1 |
| Vellenga, E | 1 |
| Wijermans, PW | 1 |
| Wittebol, S | 1 |
| Zweegman, S | 1 |
| Larocca, A | 1 |
| Falco, P | 3 |
| Falcone, AP | 1 |
| Federico, V | 1 |
| Canepa, L | 1 |
| Crugnola, M | 1 |
| Chim, CS | 1 |
| Lie, AK | 1 |
| Chan, EY | 1 |
| Leung, YY | 1 |
| Cheung, SC | 1 |
| Chan, SY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Kivivuori, SM | 1 |
| Riikonen, P | 1 |
| Valanne, L | 1 |
| Lönnqvist, T | 1 |
| Saarinen-Pihkala, UM | 1 |
| Detweiler-Short, K | 1 |
| Hayman, S | 2 |
| Kumar, S | 6 |
| Greipp, PR | 9 |
| Vincent Rajkumar, S | 1 |
| Berk, DR | 1 |
| Miller, A | 2 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Hagemeister, FB | 1 |
| Short, KD | 1 |
| Zeldenrust, S | 1 |
| Fonseca, R | 6 |
| Bergsagel, PL | 3 |
| Roy, V | 2 |
| Mikhael, JR | 2 |
| Stewart, AK | 2 |
| Laumann, K | 2 |
| Allred, JB | 2 |
| Mandrekar, SJ | 2 |
| Buadi, F | 1 |
| Klein, U | 1 |
| Neben, K | 2 |
| Hielscher, T | 1 |
| Heiss, C | 1 |
| Ho, AD | 2 |
| Goldschmidt, H | 2 |
| Wilson, SS | 1 |
| Theodorescu, D | 1 |
| Walker, BA | 1 |
| Wardell, CP | 1 |
| Chiecchio, L | 1 |
| Smith, EM | 1 |
| Boyd, KD | 1 |
| Neri, A | 1 |
| Davies, FE | 1 |
| Ross, FM | 1 |
| Morgan, GJ | 1 |
| Keizman, D | 2 |
| Zahurak, M | 2 |
| Sinibaldi, V | 1 |
| Carducci, M | 2 |
| Denmeade, S | 1 |
| Drake, C | 1 |
| Pili, R | 1 |
| Antonarakis, ES | 2 |
| Hudock, S | 1 |
| Eisenberger, M | 1 |
| San-Miguel, JF | 1 |
| Siegel, D | 2 |
| Bravo, ML | 1 |
| Dasanu, CA | 1 |
| Schwartz, RA | 1 |
| Bauer, F | 1 |
| Davis, LK | 1 |
| Silver, JS | 1 |
| Reale, MA | 1 |
| Balin, SJ | 1 |
| Wetter, DA | 1 |
| Kurtin, PJ | 1 |
| Letendre, L | 1 |
| Pittelkow, MR | 1 |
| Sher, T | 1 |
| Ailawadhi, S | 1 |
| Miller, KC | 1 |
| Manfredi, D | 1 |
| Wood, M | 1 |
| Tan, W | 1 |
| Wilding, G | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Hong, F | 1 |
| Sood, R | 1 |
| Soniwala, S | 1 |
| Lawrence, W | 1 |
| Jamshed, S | 1 |
| Masood, A | 1 |
| Iancu, D | 1 |
| Lee, K | 1 |
| Chanan-Khan, A | 2 |
| Stewart, K | 1 |
| Allred, J | 1 |
| Felipez, LM | 1 |
| Gokhale, R | 1 |
| Tierney, MP | 1 |
| Kirschner, BS | 1 |
| Swern, AS | 2 |
| Weber, D | 3 |
| Zabransky, DJ | 1 |
| Smith, HA | 1 |
| Thoburn, CJ | 1 |
| Eisenberger, MA | 1 |
| McNeel, DG | 1 |
| Lange, K | 1 |
| Hofmann, W | 1 |
| Nielsen, KV | 1 |
| Roy, L | 1 |
| Morgan, M | 2 |
| Kreipe, H | 1 |
| Petrucci, A | 1 |
| Perrone, G | 1 |
| Brioli, A | 1 |
| Zannetti, B | 1 |
| Terragna, C | 1 |
| Baccarani, M | 1 |
| Adès, L | 1 |
| Le Bras, F | 1 |
| Sebert, M | 1 |
| Eclache, V | 1 |
| Delaunay, J | 1 |
| Bouscary, D | 1 |
| Visanica, S | 1 |
| Turlure, P | 1 |
| Bresler, AG | 1 |
| Cabrol, MP | 1 |
| Banos, A | 1 |
| Blanc, M | 1 |
| Delmer, A | 1 |
| Freeman, J | 1 |
| Weiss, L | 1 |
| Kropff, M | 1 |
| Baylon, HG | 1 |
| Hillengass, J | 1 |
| Robak, T | 2 |
| Goranov, S | 1 |
| Avet-Loiseau, H | 1 |
| Moehler, TM | 1 |
| Pattou, C | 1 |
| Lucy, L | 2 |
| Kueenburg, E | 1 |
| Zerbib, R | 1 |
| Sahebi, F | 2 |
| Frankel, PH | 1 |
| Farol, L | 1 |
| Krishnan, AY | 2 |
| Cai, JL | 1 |
| Somlo, G | 3 |
| Thomas, SH | 1 |
| Reburiano, E | 1 |
| Popplewell, LL | 1 |
| Parker, PM | 1 |
| Spielberger, RT | 1 |
| Kogut, NM | 2 |
| Karanes, C | 1 |
| Htut, M | 1 |
| Ruel, C | 2 |
| Duarte, L | 1 |
| Murata-Collins, JL | 1 |
| Forman, SJ | 2 |
| Chang, HJ | 1 |
| Do, YR | 1 |
| Bae, SH | 1 |
| Lee, JL | 1 |
| Nam, SH | 1 |
| Bang, SM | 1 |
| Blin, N | 1 |
| Clavert, A | 1 |
| Roland, V | 1 |
| Loirat, M | 1 |
| Tessoulin, B | 1 |
| Le Gouill, S | 1 |
| Planche, L | 1 |
| Pennetier, M | 1 |
| Mahe, B | 1 |
| Mohty, M | 1 |
| Malard, F | 1 |
| Peterlin, P | 1 |
| Dubruille, V | 1 |
| Alegre, A | 1 |
| Oriol-Rocafiguera, A | 1 |
| Garcia-Larana, J | 1 |
| Sureda, A | 1 |
| Martinez-Chamorro, C | 1 |
| Aguado, B | 1 |
| Rosettani, B | 1 |
| Lee, KD | 1 |
| Hsiao, CH | 1 |
| Lu, YS | 1 |
| Huang, CC | 1 |
| Shen, YC | 1 |
| Montilla Morales, C | 1 |
| Gómez-Castro, S | 1 |
| Sánchez, M | 1 |
| López, R | 1 |
| Hidalgo, C | 1 |
| Del Pino-Montes, J | 1 |
| Abdel-Wahab, O | 1 |
| Pardanani, A | 1 |
| Bernard, OA | 1 |
| Finazzi, G | 1 |
| Crispino, JD | 1 |
| Kralovics, R | 1 |
| Odenike, O | 1 |
| Bhalla, K | 1 |
| Gupta, V | 1 |
| Barosi, G | 1 |
| Gotlib, J | 1 |
| Guglielmelli, P | 1 |
| Kiladjian, JJ | 1 |
| Noel, P | 1 |
| Vannucchi, AM | 1 |
| Hoffman, R | 1 |
| Barbui, T | 2 |
| Thiele, J | 1 |
| Van Etten, RA | 1 |
| Mughal, T | 1 |
| Tefferi, A | 2 |
| Wei, Z | 1 |
| Yanxia, Y | 1 |
| Ying, X | 1 |
| Han, W | 1 |
| Yuhua, J | 1 |
| Vij, R | 1 |
| Mazumder, A | 1 |
| Kaufman, JL | 1 |
| Tsao, LC | 1 |
| Westland, C | 1 |
| Singhal, AK | 1 |
| Tsujioka, T | 1 |
| Matsuoka, A | 1 |
| Tohyama, Y | 1 |
| Chanan-Khan, AA | 2 |
| Borrello, I | 2 |
| Foà, R | 2 |
| Hellmann, A | 2 |
| Jimenez-Zepeda, VH | 1 |
| Reece, DE | 2 |
| Trudel, S | 1 |
| Tiedemann, R | 1 |
| Kukreti, V | 1 |
| Brower, V | 1 |
| Laumann, KM | 1 |
| Liu, D | 1 |
| Chen, S | 1 |
| Pan, J | 1 |
| Zhu, M | 1 |
| Wu, N | 1 |
| Zhu, F | 1 |
| Chen, Z | 1 |
| Muthu Raja, KR | 1 |
| Rihova, L | 1 |
| Klincova, M | 1 |
| Penka, M | 1 |
| Jankelowitz, SK | 1 |
| Spies, JM | 1 |
| Burke, D | 1 |
| Lin, J | 1 |
| Kelly, WK | 1 |
| Wolschke, C | 1 |
| Stübig, T | 1 |
| Hegenbart, U | 1 |
| Schönland, S | 1 |
| Heinzelmann, M | 1 |
| Hildebrandt, Y | 1 |
| Ayuk, F | 1 |
| Atanackovic, D | 1 |
| Dreger, P | 1 |
| Zander, A | 1 |
| Kröger, N | 1 |
| Tunio, MA | 1 |
| Hashmi, A | 1 |
| Qayyum, A | 1 |
| Naimatullah, N | 1 |
| Masood, R | 1 |
| Sanchorawala, V | 2 |
| Patel, JM | 1 |
| Sloan, JM | 1 |
| Shelton, AC | 1 |
| Seldin, DC | 1 |
| Lauseker, M | 1 |
| Giagounidis, AA | 1 |
| Brandenburg, NA | 1 |
| Backstrom, J | 1 |
| Hasford, J | 1 |
| Biermann, JS | 1 |
| Cohen, AD | 1 |
| Devine, S | 1 |
| Djulbegovic, B | 1 |
| Faber, EA | 1 |
| Gasparetto, C | 1 |
| Hernandez-Illizaliturri, F | 1 |
| Huff, CA | 1 |
| Kassim, A | 1 |
| Liedtke, M | 1 |
| Meredith, R | 1 |
| Raje, N | 1 |
| Schriber, J | 1 |
| Stockerl-Goldstein, K | 1 |
| Treon, SP | 1 |
| Yahalom, J | 1 |
| Yunus, F | 1 |
| Shead, DA | 1 |
| Kumar, R | 1 |
| Badros, A | 1 |
| Morris, C | 1 |
| Zangari, M | 2 |
| Tricot, G | 1 |
| Horstman, AL | 1 |
| Mann, DL | 1 |
| Geyer, SM | 4 |
| Iturria, NL | 1 |
| Mohla, S | 1 |
| Weilbacher, KN | 1 |
| Cher, ML | 1 |
| Oyajobi, BO | 1 |
| Poznak, CV | 1 |
| Clohisy, DR | 1 |
| Drake, MJ | 1 |
| Robson, W | 1 |
| Mehta, P | 1 |
| Schofield, I | 1 |
| Neal, DE | 1 |
| Leung, HY | 1 |
| Iturria, N | 1 |
| Coleman, M | 1 |
| Leonard, J | 1 |
| Lyons, L | 1 |
| Pekle, K | 1 |
| Nahum, K | 1 |
| Pearse, R | 1 |
| Michaeli, J | 1 |
| Hermosilla, M | 1 |
| Ferra, C | 1 |
| Encuentra, M | 1 |
| Gallardo, D | 1 |
| Berlanga, J | 1 |
| Sarra, J | 1 |
| Grañena, A | 1 |
| Fine, HA | 2 |
| Wen, PY | 2 |
| Maher, EA | 1 |
| Viscosi, E | 1 |
| Batchelor, T | 1 |
| Lakhani, N | 1 |
| Purow, BW | 1 |
| Borkowf, CB | 1 |
| Danson, S | 1 |
| Lorigan, P | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Ranson, M | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 1 |
| Middleton, MR | 1 |
| Okikawa, Y | 2 |
| Takimoto, Y | 2 |
| Noda, M | 2 |
| Imagawa, J | 2 |
| Katayama, Y | 2 |
| Sakai, A | 2 |
| Okita, H | 2 |
| Fujimura, K | 2 |
| Kimura, A | 2 |
| Enomoto, N | 1 |
| Takei, Y | 1 |
| Hirose, M | 1 |
| Kitamura, T | 1 |
| Ikejima, K | 1 |
| Sato, N | 1 |
| Schwartz, LH | 1 |
| Mazumdar, M | 1 |
| Smith, A | 1 |
| Marion, S | 1 |
| Panicek, DM | 1 |
| Motzer, RJ | 1 |
| Dal Lago, L | 1 |
| Richter, MF | 1 |
| Cancela, AI | 1 |
| Fernandes, SA | 1 |
| Jung, KT | 1 |
| Rodrigues, AC | 1 |
| Costa, TD | 1 |
| Di Leone, LP | 1 |
| Schwartsmann, G | 1 |
| Biagi, JJ | 1 |
| Morabito, A | 1 |
| Fanelli, M | 1 |
| Carillio, G | 1 |
| Gattuso, D | 1 |
| Sarmiento, R | 1 |
| Hussein, MA | 1 |
| Kasper, B | 1 |
| Moehler, T | 1 |
| Piribauer, M | 1 |
| Czech, T | 1 |
| Dieckmann, K | 1 |
| Birner, P | 1 |
| Hainfellner, JA | 1 |
| Prayer, D | 1 |
| Fazeny-Dörner, B | 1 |
| Weinländer, G | 1 |
| Marosi, C | 1 |
| Anagnostopoulos, A | 2 |
| Hamilos, G | 1 |
| Zorzou, MP | 1 |
| Grigoraki, V | 1 |
| Anagnostou, D | 1 |
| Pawlak, WZ | 1 |
| Legha, SS | 1 |
| Ghio, R | 1 |
| Falcone, A | 1 |
| Kaufmann, H | 1 |
| Raderer, M | 1 |
| Wöhrer, S | 1 |
| Püspök, A | 1 |
| Bankier, A | 1 |
| Zielinski, C | 1 |
| Chott, A | 1 |
| Clark, PE | 1 |
| Hall, MC | 1 |
| Ridenhour, KP | 1 |
| Stindt, D | 1 |
| Lovato, JF | 1 |
| Patton, SE | 1 |
| Brinkley, W | 1 |
| Das, S | 1 |
| Torti, FM | 1 |
| Kuroda, Y | 1 |
| Schlossman, R | 1 |
| Desikan, R | 2 |
| Blood, E | 1 |
| Weller, E | 1 |
| Mitsiades, C | 1 |
| Hideshima, T | 1 |
| Davies, F | 1 |
| Doss, D | 1 |
| Freeman, A | 1 |
| Bosch, J | 1 |
| Patin, J | 3 |
| Ribatti, D | 2 |
| Scavelli, C | 1 |
| Roccaro, AM | 1 |
| Crivellato, E | 1 |
| Nico, B | 1 |
| Vacca, A | 1 |
| Pagnucco, G | 1 |
| Cardinale, G | 1 |
| Gervasi, F | 1 |
| Patt, YZ | 1 |
| Hassan, MM | 1 |
| Lozano, RD | 1 |
| Nooka, AK | 1 |
| Schnirer, II | 1 |
| Abbruzzese, JL | 2 |
| Brown, TD | 1 |
| Fleming, FJ | 1 |
| Vytopil, M | 1 |
| Chaitow, J | 1 |
| Jones, HR | 1 |
| Darras, BT | 1 |
| Ryan, MM | 1 |
| Ponzoni, M | 1 |
| Mascarenhas, RC | 1 |
| Sanghvi, AN | 1 |
| Friedlander, L | 1 |
| Geyer, SJ | 1 |
| Beasley, HS | 1 |
| Van Thiel, DH | 1 |
| Laaksonen, S | 1 |
| Remes, K | 1 |
| Koskela, K | 1 |
| Voipio-Pulkki, LM | 1 |
| Falck, B | 1 |
| Kerst, JM | 1 |
| Bex, A | 1 |
| Mallo, H | 1 |
| Dewit, L | 1 |
| Haanen, JB | 1 |
| Boogerd, W | 1 |
| Teertstra, HJ | 1 |
| de Gast, GC | 1 |
| Rezvani, K | 1 |
| Basu, S | 1 |
| Milne, AE | 1 |
| Rose, PE | 1 |
| Scott, GL | 1 |
| Rahemtulla, A | 1 |
| Samson, D | 1 |
| Apperley, JF | 1 |
| Schwartz, JD | 1 |
| Sung, M | 1 |
| Schwartz, M | 1 |
| Lehrer, D | 1 |
| Mandeli, J | 1 |
| Liebes, L | 1 |
| Goldenberg, A | 1 |
| Volm, M | 1 |
| Galli, M | 1 |
| Nicolucci, A | 1 |
| Valentini, M | 1 |
| Belfiglio, M | 1 |
| Delaini, F | 1 |
| Barbui, AM | 1 |
| Giussani, U | 1 |
| Rambaldi, A | 1 |
| Nowakowski, GS | 1 |
| McCollum, AD | 1 |
| Wu, B | 1 |
| Clark, JW | 1 |
| Kulke, MH | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Earle, CC | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
| Quek, R | 1 |
| Lim, ST | 1 |
| Ong, S | 1 |
| Lee, CP | 1 |
| Patel, PM | 1 |
| Selby, PJ | 1 |
| Hancock, BW | 1 |
| Mak, I | 2 |
| Pyle, L | 2 |
| James, MG | 1 |
| Beirne, DA | 1 |
| Steeds, S | 1 |
| A'Hern, R | 1 |
| Gore, ME | 2 |
| Solgi, G | 1 |
| Kariminia, A | 1 |
| Abdi, K | 1 |
| Darabi, M | 1 |
| Ghareghozloo, B | 1 |
| Spielberger, R | 1 |
| Fung, H | 1 |
| Falk, PM | 1 |
| Parker, P | 1 |
| Krishnan, A | 1 |
| Rodriguez, R | 1 |
| Nakamura, R | 1 |
| Nademanee, A | 1 |
| Popplewell, L | 1 |
| Frankel, P | 1 |
| Tin, R | 1 |
| Ilieva, P | 1 |
| Laber, DA | 2 |
| Okeke, RI | 1 |
| Arce-Lara, C | 1 |
| Taft, BS | 2 |
| Schonard, CL | 1 |
| McMasters, KM | 1 |
| Kloecker, GH | 2 |
| Miller, DM | 1 |
| Corvatta, L | 2 |
| Piersantelli, MN | 2 |
| Visani, G | 1 |
| Alesiani, F | 1 |
| Brunori, M | 1 |
| Galieni, P | 1 |
| Catarini, M | 1 |
| Burattini, M | 1 |
| Centurioni, R | 1 |
| Ferranti, M | 1 |
| Rupoli, S | 1 |
| Scortechini, AR | 1 |
| Giuliodori, L | 1 |
| Candela, M | 1 |
| Capelli, D | 1 |
| Montanari, M | 1 |
| Olivieri, A | 1 |
| Polloni, C | 2 |
| Marconi, M | 2 |
| Leoni, P | 2 |
| Laurenti, L | 1 |
| Piccioni, P | 1 |
| Tarnani, M | 1 |
| De Padua, L | 1 |
| Garzia, M | 1 |
| Efremov, DG | 1 |
| Piccirillo, N | 1 |
| Chiusolo, P | 1 |
| Sica, S | 1 |
| Leone, G | 1 |
| Moreno-Aspitia, A | 1 |
| Colon-Otero, G | 1 |
| Niedringhaus, RD | 1 |
| Vukov, A | 1 |
| Li, CY | 1 |
| Menke, DM | 1 |
| Alberts, SR | 1 |
| Schoeman, JF | 1 |
| Fieggen, G | 1 |
| Seller, N | 1 |
| Mendelson, M | 1 |
| Hartzenberg, B | 1 |
| Vaishampayan, UN | 1 |
| Heilbrun, LK | 1 |
| Shields, AF | 1 |
| Lawhorn-Crews, J | 1 |
| Baranowski, K | 1 |
| Smith, D | 1 |
| Flaherty, LE | 1 |
| Wechalekar, AD | 1 |
| Goodman, HJ | 1 |
| Lachmann, HJ | 1 |
| Offer, M | 1 |
| Hawkins, PN | 1 |
| Gillmore, JD | 1 |
| Kabat, B | 2 |
| Mathew, P | 1 |
| Dieringer, PY | 1 |
| Chen, I | 1 |
| Pagliaro, LC | 1 |
| Bekele, BN | 1 |
| Daliani, DD | 1 |
| Martino, M | 1 |
| Console, G | 1 |
| Callea, V | 1 |
| Stelitano, C | 1 |
| Massara, E | 1 |
| Irrera, G | 1 |
| Messina, G | 1 |
| Iacopino, P | 1 |
| Bauditz, J | 1 |
| Lochs, H | 1 |
| Voderholzer, W | 1 |
| Schrader, AJ | 1 |
| Heidenreich, A | 1 |
| Hegele, A | 1 |
| Olbert, P | 1 |
| Varga, Z | 1 |
| Hofmann, R | 1 |
| McGowan, N | 1 |
| Avonto, I | 2 |
| Gordinier, ME | 1 |
| Dizon, DS | 1 |
| Weitzen, S | 1 |
| Disilvestro, PA | 1 |
| Moore, RG | 1 |
| Granai, CO | 1 |
| Dowlati, A | 2 |
| Subbiah, S | 1 |
| Cooney, M | 1 |
| Rutherford, K | 1 |
| Mekhail, T | 1 |
| Fu, P | 1 |
| Chapman, R | 1 |
| Ness, A | 2 |
| Cortas, T | 1 |
| Saltzman, J | 1 |
| Levitan, N | 1 |
| Warren, G | 1 |
| Roussou, M | 1 |
| Barmparousi, D | 1 |
| Koutsoukou, V | 1 |
| Chawla, S | 1 |
| Smart, CJ | 1 |
| Moots, RJ | 1 |
| Sandri, MT | 1 |
| Johansson, HA | 1 |
| Zorzino, L | 1 |
| Salvatici, M | 1 |
| Passerini, R | 1 |
| Maisonneuve, P | 1 |
| Rocca, A | 1 |
| Peruzzotti, G | 1 |
| Colleoni, M | 1 |
| Khan, MI | 1 |
| Schonard, C | 1 |
| Salvador, C | 1 |
| Ambrosini, MT | 1 |
| Bruno, B | 1 |
| Abidi, MH | 1 |
| Tove, I | 1 |
| Ibrahim, RB | 1 |
| Maria, D | 1 |
| Peres, E | 1 |
| Solti, M | 1 |
| Berd, D | 1 |
| Mastrangelo, MJ | 1 |
| Sato, T | 1 |
| Faria, SC | 1 |
| Ng, CS | 1 |
| Hess, KR | 1 |
| Phongkitkarun, S | 1 |
| Szejnfeld, J | 1 |
| Daliani, D | 1 |
| Charnsangavej, C | 1 |
| Zhang, HG | 1 |
| Qin, SK | 1 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 1 |
| Ain, KB | 1 |
| Lee, C | 1 |
| Williams, KD | 1 |
| Liew, MS | 1 |
| Bishton, MJ | 1 |
| Januszewicz, H | 1 |
| Alatakis, S | 1 |
| Geyer, S | 1 |
| Lee, SM | 1 |
| James, L | 1 |
| Snee, M | 1 |
| Ellis, P | 1 |
| Hackshaw, A | 1 |
| Lau, H | 1 |
| Kong, L | 1 |
| Kumar, G | 1 |
| Laskin, OL | 1 |
| Masliak, Z | 1 |
| Faiman, B | 1 |
| Nagler, A | 1 |
| Zhuang, SH | 1 |
| Catalano, J | 1 |
| Jedrzejczak, W | 1 |
| Haessler, J | 1 |
| Hicks, LK | 1 |
| Haynes, AE | 1 |
| Walker, IR | 1 |
| Herst, JA | 1 |
| Meyer, RM | 1 |
| Imrie, K | 1 |
| Ciolli, S | 1 |
| Leoni, F | 1 |
| Casini, C | 1 |
| Breschi, C | 1 |
| Batts, ED | 1 |
| Hegerfeldt, Y | 1 |
| Lazarus, HM | 1 |
| Candoni, A | 1 |
| Simeone, E | 1 |
| Fanin, R | 1 |
| Sanborn, SL | 1 |
| Cooney, MM | 1 |
| Brell, JM | 1 |
| Krishnamurthi, S | 1 |
| Gibbons, J | 1 |
| Bokar, JA | 1 |
| Nock, C | 1 |
| Remick, SC | 1 |
| Sastry, PS | 1 |
| Mehta, J | 1 |
| Ayers, D | 1 |
| Roberson, P | 1 |
| Eddlemon, P | 1 |
| Munshi, N | 1 |
| Wilson, C | 1 |
| Dhodapkar, M | 1 |
| Zeddis, J | 1 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Loeffler, JS | 1 |
| Levin, VA | 1 |
| Black, PM | 1 |
| Kaplan, R | 1 |
| Pluda, JM | 3 |
| Yung, WK | 1 |
| Little, RF | 1 |
| Wyvill, KM | 1 |
| Welles, L | 1 |
| Marshall, V | 1 |
| Newcomb, FM | 1 |
| Tosato, G | 1 |
| Feigal, E | 1 |
| Steinberg, SM | 1 |
| Whitby, D | 1 |
| Goedert, JJ | 1 |
| Esteve, J | 1 |
| Kyrtsonis, MC | 1 |
| Kokoris, SI | 1 |
| Kontopidou, FN | 1 |
| Siakantaris, MP | 1 |
| Kittas, C | 1 |
| Pangalis, GA | 1 |
| Short, SC | 1 |
| Traish, D | 1 |
| Dowe, A | 1 |
| Hines, F | 1 |
| Gore, M | 1 |
| Brada, M | 1 |
| Krown, SE | 1 |
| Stebbing, J | 1 |
| Benson, C | 1 |
| Smalley, K | 1 |
| Bridle, H | 1 |
| Sapunar, F | 1 |
| Ahern, R | 1 |
| Avigdor, A | 1 |
| Raanani, P | 1 |
| Levi, I | 1 |
| Hardan, I | 1 |
| Ben-Bassat, I | 1 |
| Tseng, JE | 1 |
| Glisson, BS | 1 |
| Khuri, FR | 1 |
| Shin, DM | 1 |
| Myers, JN | 1 |
| El-Naggar, AK | 1 |
| Roach, JS | 1 |
| Ginsberg, LE | 1 |
| Thall, PF | 1 |
| Teddy, S | 1 |
| Lawhorn, KN | 1 |
| Zentgraf, RE | 1 |
| Steinhaus, GD | 1 |
| Hong, WK | 1 |
| Herbst, RS | 1 |
| Marx, GM | 1 |
| McCowatt, S | 1 |
| Boyle, FM | 1 |
| Levi, JA | 1 |
| Bell, DR | 1 |
| Cook, R | 1 |
| Biggs, M | 1 |
| Little, N | 1 |
| Wheeler, HR | 1 |
| Ahmad, I | 1 |
| Islam, T | 1 |
| Hahn, T | 1 |
| Wentling, D | 1 |
| Becker, JL | 1 |
| Alam, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635] | Phase 3 | 159 participants (Actual) | Interventional | 2000-03-01 | Completed | ||
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571] | Phase 3 | 108 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes[NCT00179621] | Phase 3 | 205 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-dependent Subjects With Myelodysplastic Syndromes Associated With a Del(5q) Cytogenetic Abnormality.[NCT00065156] | Phase 2 | 148 participants (Actual) | Interventional | 2003-06-01 | Completed | ||
| A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China[NCT01947309] | 176 participants (Actual) | Observational | 2013-11-30 | Terminated (stopped due to Business Decision) | |||
| An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients[NCT04802356] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial[NCT01545804] | Phase 2 | 55 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| CLLM1-Protocol of the German CLL-Study Group (GCLLSG) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for High-risk Patients With Chro[NCT01556776] | Phase 3 | 89 participants (Actual) | Interventional | 2012-07-20 | Completed | ||
| A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.[NCT02341781] | 30 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| Observational, Non-interventional, Multicenter Study Aimed at Collecting Retrospective/Prospective 648/96 Italian Registry Data Related to Lenalidomide (Revlimid®) Prescription to Patients With Myelodysplastic Syndromes[NCT01347944] | 149 participants (Actual) | Observational | 2011-01-01 | Completed | |||
| Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma[NCT00603447] | Phase 1 | 84 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL[NCT04423926] | Phase 1/Phase 2 | 91 participants (Anticipated) | Interventional | 2020-06-10 | Recruiting | ||
| A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma[NCT00655668] | Phase 2 | 54 participants (Actual) | Interventional | 2008-03-01 | Terminated (stopped due to Decision not to pursue as single agent in the study population.) | ||
| Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.[NCT03964480] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-10-14 | Recruiting | |||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma[NCT01593410] | Phase 2 | 194 participants (Actual) | Interventional | 2010-08-01 | Completed | ||
| A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT[NCT00799513] | Phase 2 | 47 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma[NCT01021423] | Phase 3 | 9 participants (Actual) | Interventional | 2010-04-01 | Terminated (stopped due to Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.) | ||
| A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma[NCT00765245] | Phase 2 | 44 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)[NCT00907348] | Phase 2 | 49 participants (Anticipated) | Interventional | 2007-10-31 | Active, not recruiting | ||
| Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma[NCT01035463] | Phase 1/Phase 2 | 74 participants (Actual) | Interventional | 2009-11-12 | Completed | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortez[NCT00737529] | Phase 2 | 134 participants (Actual) | Interventional | 2008-12-22 | Completed | ||
| Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma[NCT01351623] | Phase 2 | 44 participants (Actual) | Interventional | 2011-05-09 | Completed | ||
| [NCT00006198] | Phase 2 | 0 participants | Interventional | Active, not recruiting | |||
| A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation[NCT01194791] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-10-31 | Completed | ||
| A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma[NCT01311687] | Phase 3 | 455 participants (Actual) | Interventional | 2011-03-11 | Completed | ||
| A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory[NCT00238238] | Phase 2 | 97 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects[NCT01091831] | Phase 3 | 389 participants (Actual) | Interventional | 2009-07-31 | Active, not recruiting | ||
| A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an[NCT00689936] | Phase 3 | 1,623 participants (Actual) | Interventional | 2008-08-21 | Completed | ||
| A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd)[NCT01237249] | Phase 2 | 250 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)[NCT01754857] | Phase 2 | 36 participants (Actual) | Interventional | 2013-11-12 | Completed | ||
| A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma[NCT01698801] | Phase 2 | 26 participants (Actual) | Interventional | 2012-10-01 | Completed | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma[NCT01724177] | Phase 2 | 26 participants (Actual) | Interventional | 2012-11-12 | Completed | ||
| A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma[NCT03710915] | Phase 1 | 3 participants (Actual) | Interventional | 2019-01-12 | Terminated (stopped due to Company decision) | ||
| A Phase II Study Of Thalidomide And CPT-11 (IRINOTECAN) Following Radiotherapy For Glioblastoma Multiforme[NCT00039468] | Phase 2 | 26 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma[NCT00083382] | Phase 2 | 83 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| Salvage in Patients With Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Lenalidomide as a Second-line Therapy[NCT01673308] | Phase 2 | 35 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | ||
| A Multicenter Phase I/II Trial Evaluating the Safety and Efficacy of Lenalidomide (Revlimid, CC-5013) in Combination With Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma[NCT00306813] | Phase 1/Phase 2 | 53 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma[NCT00065351] | Phase 2 | 222 participants (Actual) | Interventional | 2003-07-01 | Completed | ||
| A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
| An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT00048230] | Phase 3 | 620 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy[NCT00057616] | Phase 3 | 274 participants | Interventional | 2002-10-01 | Completed | ||
| The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.[NCT00424047] | Phase 3 | 351 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma[NCT00056160] | Phase 3 | 353 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| A Phase II Trial of Revlimid, Cyclophosphamide, and Dexamethasone in Patients With > Newly Diagnosed Active Multiple Myeloma[NCT00478218] | Phase 2 | 53 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma[NCT00452569] | Phase 3 | 499 participants (Actual) | Interventional | 2006-02-01 | Completed | ||
| A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma[NCT00420849] | Phase 3 | 587 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma[NCT00432458] | Phase 3 | 68 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| Dose-finding Study of Lenalidomide as Maintenance Therapy in Multiple Myeloma After Allogeneic Stem Cell Transplantation[NCT00778752] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis[NCT00679367] | Phase 2 | 16 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [NCT00261612] | Phase 2 | 16 participants | Interventional | 2005-01-31 | Active, not recruiting | ||
| Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients[NCT02384083] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study[NCT01675141] | Phase 2 | 11 participants (Actual) | Interventional | 2012-08-20 | Terminated (stopped due to Original investigator left the NIH and the primary outcome was not reached) | ||
| Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression[NCT00006006] | Phase 2 | 38 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Thalidomide-Dexamethasone vs Alpha-Interferon-Dexamethasone as Maintenance Therapy After Thalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin Combination for[NCT00633542] | Phase 3 | 103 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis[NCT00607581] | Phase 2 | 21 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Frontline Thalidomide for Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide[NCT02966522] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure[NCT02622906] | Phase 2 | 24 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial[NCT03062800] | Phase 2 | 232 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma[NCT01297764] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2011-04-30 | Active, not recruiting | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma[NCT01701076] | Phase 2 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma[NCT00103506] | Phase 3 | 646 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma[NCT00057564] | Phase 3 | 470 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Safety and Efficacy Assessments of Osalmid in the Treatment of Multiple Myeloma[NCT03670173] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2018-10-01 | Active, not recruiting | ||
| Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles[NCT00049296] | Phase 1 | 26 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.[NCT00232934] | Phase 3 | 400 participants | Interventional | 2002-01-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA[NCT00019123] | Phase 2 | 0 participants | Interventional | 1996-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Thalidomide | 117 |
| Placebo | 98 |
Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Thalidomide | 15 |
| Placebo | 9.6 |
"The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL).~In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL." (NCT00179621)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -2.5 |
| Lenalidomide 5 mg | 5.9 |
| Lenalidomide 10 mg | 5.8 |
The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL. (NCT00179621)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -1.1 |
| Lenalidomide 5 mg | 5.6 |
| Lenalidomide 10 mg | 4.9 |
The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL. (NCT00179621)
Timeframe: Baseline, Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.8 |
| Lenalidomide 5 mg | 4.8 |
| Lenalidomide 10 mg | 3.9 |
Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included. (NCT00179621)
Timeframe: up to 3 years
| Intervention | Weeks (Mean) |
|---|---|
| Placebo | 61.4 |
| Lenalidomide 5 mg | 107.7 |
| Lenalidomide 10 mg | 108.6 |
Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study. (NCT00179621)
Timeframe: up to 3 years
| Intervention | Months (Median) |
|---|---|
| Placebo | 42.4 |
| Lenalidomide 5 mg | NA |
| Lenalidomide 10 mg | 44.5 |
For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized. (NCT00179621)
Timeframe: Baseline, up to 52 weeks
| Intervention | g/dL (Mean) |
|---|---|
| Placebo | 2.0 |
| Lenalidomide 5 mg | 5.5 |
| Lenalidomide 10 mg | 6.0 |
Count of participant deaths throughout the entire study and reported by the original treatment assignment. (NCT00179621)
Timeframe: up to 3 years
| Intervention | Participants (Number) |
|---|---|
| Placebo | 35 |
| Lenalidomide 5 mg | 32 |
| Lenalidomide 10 mg | 34 |
The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period. (NCT00179621)
Timeframe: Up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Placebo | 3 |
| Lenalidomide 5 mg | 20 |
| Lenalidomide 10 mg | 23 |
Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period. (NCT00179621)
Timeframe: Up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Placebo | 4 |
| Lenalidomide 5 mg | 24 |
| Lenalidomide 10 mg | 25 |
The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented. (NCT00179621)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major response | Minor response | Cytogenetic progression | Not evaluable/data not available | |
| Lenalidomide 10 mg | 10 | 7 | 8 | 1 |
| Lenalidomide 5 mg | 5 | 3 | 10 | 10 |
| Placebo | 0 | 0 | 5 | 10 |
Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe. (NCT00179621)
Timeframe: up to 3 years
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Double-Blind (first 16 weeks) | Double-Blind (52 weeks) | Double-Blind + Open-Label | |
| Lenalidomide 10 mg | 0 | 2 | 15 |
| Lenalidomide 5 mg | 2 | 7 | 16 |
| Placebo | 2 | 4 | 21 |
The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) <5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with <5% blasts pretreatment with an on study blast increase of 50% which is now >5% showed bone marrow progression. (NCT00179621)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Complete remission | Partial remission | Stable Disease | Progression | |
| Lenalidomide 10 mg | 12 | 1 | 33 | 3 |
| Lenalidomide 5 mg | 7 | 5 | 35 | 4 |
| Placebo | 0 | 0 | 37 | 3 |
A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase <500/mm^3. (NCT00179621)
Timeframe: up to week 52
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major | Minor | None | |
| Lenalidomide 10 mg | 2 | 1 | 14 |
| Lenalidomide 5 mg | 3 | 0 | 15 |
| Placebo | 1 | 0 | 9 |
The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of <100,000/mm^3 as an absolute increase of ≥30,000/mm^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm^3 but less than 30,000/mm^3. (NCT00179621)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major | Minor | None | |
| Lenalidomide 10 mg | 1 | 0 | 3 |
| Lenalidomide 5 mg | 1 | 0 | 5 |
| Placebo | 0 | 0 | 3 |
"Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.~The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE." (NCT00179621)
Timeframe: up to week 52
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At least one AE | At least one AE related to study drug | At least one NCI CTCAE grade 3-4 AE | At least one related NCI CTCAE grade 3-4 AE | At least one serious AE | At least one serious AE related to study drug | An AE leading to discontinuation of study drug | An AE leading to dose reduction or interruption | Deaths within 30 days of last dose of study drug | |
| Lenalidomide 10 mg | 69 | 66 | 65 | 61 | 32 | 13 | 6 | 51 | 4 |
| Lenalidomide 5 mg | 69 | 68 | 62 | 61 | 31 | 17 | 12 | 44 | 2 |
| Placebo | 64 | 34 | 29 | 13 | 14 | 1 | 3 | 5 | 4 |
The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline. (NCT00065156)
Timeframe: Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)
| Intervention | g/dL (Mean) |
|---|---|
| Lenalidomide | 6.1 |
Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence. (NCT00065156)
Timeframe: up to 2 years
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 97.0 |
"Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive rolling 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin." (NCT00065156)
Timeframe: Up to 2 years
| Intervention | participants (Number) |
|---|---|
| Lenalidomide | 59 |
A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment). (NCT00065156)
Timeframe: Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)
| Intervention | participant (Number) |
|---|---|
| Lenalidomide | 70 |
"Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive rolling 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period." (NCT00065156)
Timeframe: up to 2 years
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide | 6.2 |
"Major neutrophil response: participants with a minimum pretreatment ANC concentration of < 1500/mm^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of~≥ 500/mm^3, whichever was greater (at least to be ≥ 500/mm^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of < 1500/mm^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days." (NCT00065156)
Timeframe: up to 2 years
| Intervention | participant (Number) | ||
|---|---|---|---|
| Major | Minor | None | |
| Lenalidomide | 9 | 0 | 18 |
"Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least~1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline." (NCT00065156)
Timeframe: up to 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major | Minor | None | |
| Lenalidomide | 18 | 20 | 14 |
"Major platelet response: participants with a minimum pretreatment platelet of <100,000/mm^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence.~Minor platelet response: participants with a minimum pretreatment platelet of <100,000/mm^3, a ≥ 50% increase in platelet count with a net increase >10,000/mm^3 for a consecutive 56-day period in the absence of platelet transfusions." (NCT00065156)
Timeframe: up to 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major | Minor | None | |
| Lenalidomide | 2 | 0 | 13 |
"Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive rolling 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study." (NCT00065156)
Timeframe: up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Relapsed (had a transfusion after response) | Maintained transfusion independence | |
| Lenalidomide | 35 | 24 |
"Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.~The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE." (NCT00065156)
Timeframe: Up to 2 Years
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| At least one AE | At least one AE related to study drug | At least one NCI CTC grade 3-4 AE | At least one NCI CTC grade 3-4 AE related to drug | At least one serious AE | At least one serious AE related to study drug | AE leading to dose reduction or interruption | AE leading to discontinuation of study drug | |
| Lenalidomide | 148 | 143 | 140 | 131 | 89 | 40 | 131 | 47 |
"Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics):~Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB).~Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML)." (NCT00065156)
Timeframe: up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| RA/RARS to RAEB | RA/RARS/RAEB/CMML to AML | |
| Lenalidomide | 11 | 6 |
Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist. (NCT00065156)
Timeframe: up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Complete bone marrow improvement | Partial bone marrow improvement | |
| Lenalidomide | 22 | 15 |
"Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic~≥ Grade 2 neuropathy with pain~≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide)~≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy~≥ Grade 4 fatigue persisting > 7 days~Treatment delay for toxicity > 21 days~Hematologic~Grade 4 neutropenia (absolute neutrophil count [ANC] < 500/mm³) > 7 days~Febrile neutropenia (ANC < 1,000/mm³ with fever ≥ 38.3ºC)~Grade 4 thrombocytopenia (platelets < 25,000/mm³) for > 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding~Treatment delay for toxicity > 21 days.~The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort." (NCT00603447)
Timeframe: Cycle 1, 28 days
| Intervention | participants (Number) |
|---|---|
| 1: CFZ 15 mg/m² + LEN 10 mg | 0 |
| 2: CFZ 15 mg/m² + LEN 15 mg | 0 |
| 3: CFZ 15 mg/m² + LEN 20 mg | 0 |
| 4: CFZ 20 mg/m² + LEN 20 mg | 0 |
| 5: CFZ 20 mg/m² + LEN 25 mg | 0 |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | 1 |
"Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.~Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy." (NCT00603447)
Timeframe: From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any adverse event | Treatment-related adverse event | Grade 3 or higher adverse event | Treatment-related Grade 3 or higher adverse event | Serious adverse event | AE leading to discontinuation of any study drug | AE leading to discontinuation of carfilzomib | Deaths within 30 days of last dose of study drug | |
| 1: CFZ 15 mg/m² + LEN 10 mg | 6 | 4 | 5 | 1 | 3 | 1 | 0 | 0 |
| 2: CFZ 15 mg/m² + LEN 15 mg | 6 | 5 | 6 | 4 | 3 | 1 | 0 | 0 |
| 3: CFZ 15 mg/m² + LEN 20 mg | 8 | 8 | 8 | 7 | 4 | 3 | 1 | 0 |
| 4: CFZ 20 mg/m² + LEN 20 mg | 6 | 4 | 6 | 4 | 4 | 4 | 2 | 0 |
| 5: CFZ 20 mg/m² + LEN 25 mg | 6 | 6 | 6 | 6 | 3 | 2 | 1 | 0 |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | 8 | 8 | 8 | 8 | 6 | 3 | 1 | 0 |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | 44 | 43 | 41 | 38 | 22 | 18 | 9 | 3 |
Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma. (NCT00655668)
Timeframe: Up to 24 months
| Intervention | Months (Median) |
|---|---|
| Single Agent Lenalidomide | 3.55 |
Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause. (NCT00655668)
Timeframe: Up to 24 months
| Intervention | Months (Median) |
|---|---|
| Single Agent Lenalidomide | 2.53 |
"Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail):~Complete Response(CR): Complete disappearance of all detectable disease~Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow~Partial Response(PR): >50% decrease in six largest nodes/nodal masses~Stable Disease(SD): Less than PR, but not progressive disease~Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by >=50% in previous sites~Progressive Disease(PD): >=50% increase from low in PR/Non-Responders" (NCT00655668)
Timeframe: Up to 24 months
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Complete Response Unconfirmed (CRu) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | No Response Assessment | Other | Tumor Control (CR+CRu+PR+SD) | |
| Single Agent Lenalidomide | 4 | 2 | 6 | 16 | 16 | 9 | 1 | 28 |
Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.) (NCT00655668)
Timeframe: Up to 24 months
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| At least 1 adverse event (AE) | At least 1 AE related to drug | At least 1 NCI CTCAE Grade 3-4 AE | At least 1 NCI CTCAE Gr 3-4 AE related to drug | At least 1 serious adverse event (SAE) | At least 1 SAE related to drug | At least 1 AE leading to drug withdrawal (WD) | At least 1 AE leading to drug interruption/WD | |
| Single Agent Lenalidomide | 53 | 40 | 34 | 19 | 29 | 16 | 21 | 19 |
"Participants with treatment-emergent adverse events (TEAEs) during the treatment period plus 30 days. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.~The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE." (NCT01021423)
Timeframe: up to 9 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| At least one TEAE | At least one TEAE related to study drug | At least one NCI CTC grade 3-4 TEAE | At least one NCI CTC grade 3-4 related to drug | At least one serious TEAE | At least one serious TEAE related to drug | TEAE leading to discontinuation of drug | Related TEAE leading to discontinuation of drug | TEAE leading to dose reduction or interruption | Related TEAE - dose reduction or interruption | |
| Lenalidomide | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Placebo | 4 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
Disease-free survival is the time from on-treatment to first relapse or death (whichever comes first). Those who are alive and without relapse are censored at the last date known alive. (NCT00765245)
Timeframe: From on-treatment date to disease recurrence, up to 1 year
| Intervention | years (Mean) |
|---|---|
| Arm I: Lenalidomide | 0.818 |
| Arm II: Lenalidomide and Rituximab IV | 0.90 |
Disease-free survival is the estimated probable duration of life from on-study date to date of death from any cause, using the Kaplan-Meier method where death is an event, with censoring for non-expired patients at last known date alive. (NCT00765245)
Timeframe: From on-treatment date to disease recurrence, up to 2 years
| Intervention | years (Median) |
|---|---|
| Arm I: Lenalidomide | 0.818 |
| Arm II: Lenalidomide and Rituximab IV | 0.757 |
Count of patients according to the worst-grade toxicity experienced by each, where worst-grade toxicity is per NCI common toxicity criteria: grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening; grade 5, death. Toxicities present at baseline and continuing without change in grade are excluded when considering worst-grade toxicity. (NCT00765245)
Timeframe: 30 days after completing treatment, for up to 13 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Number of patients with WGT=1 | Number of patients with WGT=2 | Number of patients with WGT=3 | Number of patients with WGT=4 | Number of patients with WGT=5 | |
| Arm I: Lenalidomide | 2 | 6 | 6 | 5 | 0 |
| Arm II: Lenalidomide and Rituximab IV | 0 | 8 | 8 | 5 | 0 |
The Kaplan-Meier method will be used to estimate the event-free survival distribution. (NCT01035463)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| All Phase I Participants | 84 |
| All Phase II Participants | 87 |
The Maximum Tolerated Dose (MTD) is defined to be the dose cohort below which 3 out of 6 subjects experience dose limiting toxicities during cycle 1. Dose limiting toxicities graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCT01035463)
Timeframe: Cycle 1, 28 days
| Intervention | milligrams PO daily (Number) |
|---|---|
| Treatment (Stem Cell Transplantation) | 10 |
The Kaplan-Meier method will be used to estimate the overall survival distribution. This outcome only reports data as it pertains to overall survival at one year. All-cause mortality includes survival for follow up for all subjects on the study. (NCT01035463)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| All Phase I Participants | 100 |
| All Phase II Participants | 95 |
Kaplan Meier estimates for the duration of CR/CRu was calculated from the date of the first occurrence of CR/CRu to the date of documented disease progression or death (without documented progression) for participants who obtained a CR/CRu; participants who had not progressed (or died) were censored at the last valid assessment. (NCT00737529)
Timeframe: From Day 1 of study drug to progression or early discontinuation; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 24.43 |
Kaplan Meier estimate for the duration of response (DoR) was calculated from the date of the first occurrence of initial response for responders (demonstrating evidence of at least a PR) to the date of first documented disease progression (any new lesion or increase by ≥ 50% of previously involved sites from nadir) or death (without documented progression) for participants who responded; participants who had not progressed (or died) were censored at the last valid assessment. (NCT00737529)
Timeframe: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days.
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 16.64 |
Kaplan Meier estimate of time to progression was calculated as time from the start of the study drug therapy to the first observation of disease progression. Participants who died without progression were censored at the date of death; otherwise, the censoring rules presented above for PFS applied to the analysis of TTP. Progressive Disease(PD): Appearance of new lesion or increase by ≥50% from previously involved sites from nadir (NCT00737529)
Timeframe: From Day 1 of study drug to first documented time of progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 5.46 |
Kaplan Meier estimates of PFS was defined as the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever comes first. If a participant had not progressed or died, PFS was censored at the time of last adequate assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last adequate tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented date of disease progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 4.01 |
Time to treatment failure (TTF) was calculated from the start of study drug therapy to early discontinuation from treatment due to any cause, including disease progression, toxicity, or death and was based on site-reported data. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented time of treatment failure; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.75 |
Kaplan Meier estimate of overall survival was calculated from the time the first dose of study drug to death from any cause. Participants who had not died were censored at the last date the participant was known to be alive. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented date of progressive disease or death; up to the final data cut-off date of 30 March 2017; median duration of follow-up for surviving participants was 62.94 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 19.50 |
Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed, or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. (NCT00737529)
Timeframe: From Day 1 of study treatment to progession or early treatment discontinuation; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 29.9 |
The percentage of participants whose best response was CR or CRu. Participants who had discontinued before CR/CRu was observed, or changed to other anti-lymphoma treatments before a CR/CRu response had been observed, were considered as non-responders. CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow. (NCT00737529)
Timeframe: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 9.0 |
Time to Complete Response (CR+CRu) was defined as the time from the first dose of study drug to the date of the first occurrence of at least CRu and was calculated only for participants with CR or CRu. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented CR/CRu or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.9 |
Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants. (NCT00737529)
Timeframe: From Day 1 of study drug to time of first documented PR or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.5 |
Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. (NCT00737529)
Timeframe: From the first dose of lenalidomide through 28 days after the last dose during the follow-up phase; median (minimum, maximum) duration of treatment was 94.0 (1.0, 1950 days)
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any TEAE Related to Investigational Product (IP) | Any TEAE Grade 3-5 AE | Any TEAE Grade 3 AE | Any TEAE Grade 4 AE | Any TEAE Grade 5 AE | Any Grade 3-5 AE Related to IP | Any Grade 3 AE Related to IP | Any Grade 4 AE Related to IP | Any Grade 5 AE Related to IP | Any TEAE Serious Adverse Event (SAE) | Any SAE Related to IP | Any TEAE Leading to Stopping of IP | Any Treatment Related AE Leading to Stopping IP | Any AE Leading to Dose Reduction | Any AE Leading to IP Interruption | Any Treatment Related AE Leading to Dose Reduction | Treatment Related AE Leading to IP Interruption | |
| Lenalidomide | 132 | 118 | 106 | 101 | 57 | 18 | 90 | 88 | 41 | 2 | 70 | 30 | 28 | 16 | 55 | 81 | 52 | 66 |
Duration of response (calculated for responders only) is defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria assessed by the Independent Response Adjudication Committee. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 35.1 |
| High-Dose Dexamethasone | 28.1 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 07 September 2012. Maximum time on follow-up for survival was 70 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | NA |
| High-Dose Dexamethasone | 34.0 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 29 August 2017. Maximum time on follow-up for survival was 324 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 56.1 |
| High-Dose Dexamethasone | 35.3 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up for survival was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 54.0 |
| High-Dose Dexamethasone | 34.9 |
Objective response is defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the Independent Response Adjudication Committee: SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 23.5 |
| High-Dose Dexamethasone | 3.9 |
Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the Independent Response Adjudication Committee: CR requires all of the following: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - <5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to < 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 22.2 |
| High-Dose Dexamethasone | 3.3 |
Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease required 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 15.7 |
| High-Dose Dexamethasone | 8.0 |
Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 16.0 |
| High-Dose Dexamethasone | 8.1 |
"Time to improvement in bone pain is defined as the time from randomization to at least one category improvement from Baseline in bone pain category. Bone pain was categorized (from best to worst) according to answers to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for patients with Multiple Myeloma Module (QLQ-MY20), Question 1, Have you had bone aches or pain?: 1) Not at all, 2) A little, 3) Quite a bit, or 4) Very much." (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 5.7 |
| High-Dose Dexamethasone | 4.1 |
Time to improvement in ECOG performance status defined as the time from randomization until at least a one category improvement from Baseline in ECOG performance status score. The categories of the ECOG Performance Status Scale are as follows: -0: Fully active, able to carry on all pre-disease performance without restriction; -1: Restricted in physically strenuous activity but ambulatory and able to carry our work of a light or sedentary nature, e.g., light housework, office work; -2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. Patients with a score of 3, 4 or 5 were excluded from participating in the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 8.1 |
| High-Dose Dexamethasone | 4.3 |
Time to improvement in renal function is defined as the time from randomization to at least one category improvement from Baseline in renal function. Renal Function was categorized as (from best to worst): - Normal: creatinine clearance ≥80 mL/min; - Grade 1: creatinine clearance ≥60 to <80 mL/min; - Grade 2 : creatinine clearance ≥45 to < 60 mL/min. Participants with creatinine clearance < 45 mL/min at baseline were excluded from the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 4.6 |
| High-Dose Dexamethasone | 4.1 |
Time to progression (TTP) is calculated as the time from randomization to the first documented progression confirmed by a blinded, independent Response Adjudication Committee and based on the International Myeloma Working Group Uniform Response criteria (IMWG). Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 20.0 |
| High-Dose Dexamethasone | 9.0 |
Time to response is calculated as the time from randomization to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 8.1 |
| High-Dose Dexamethasone | 10.5 |
Time to increased hemoglobin, defined as the time from randomization to at least one category improvement from Baseline in common terminology criteria for adverse events (CTCAE) grade for hemoglobin level. Hemoglobin categories are: 1) Normal; 2) CTCAE Grade 1: < lower limit of normal (LLN) to 10.0 g/dL; 3) CTCAE Grade 2: < 10.0 to <8.0 g/dL. Participants with CTCAE Grade 3 anemia or worse at Baseline were excluded from the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 3.4 |
| High-Dose Dexamethasone | 1.3 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -2.87 | -5.66 | -6.31 | -8.64 | -4.17 |
| Pomalidomide Plus Low-Dose Dexamethasone | 1.22 | 2.40 | 2.44 | 1.91 | 0.19 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 4.03 | 7.76 | 9.43 | 9.47 | 10.49 |
| Pomalidomide Plus Low-Dose Dexamethasone | 2.43 | 3.26 | 1.71 | 0.21 | 0.99 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reductions in pain (i.e. improvement in symptom) and positive values indicate increases in pain (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 0.36 | 2.83 | 3.03 | 2.47 | 10.19 |
| Pomalidomide Plus Low-Dose Dexamethasone | -2.70 | -3.58 | -2.41 | -1.64 | -2.40 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -3.96 | -9.69 | -8.08 | -5.43 | -4.81 |
| Pomalidomide Plus Low-Dose Dexamethasone | -2.32 | -0.56 | 0.17 | 0.91 | 0.54 |
The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Side Effects Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction in side effects (i.e.improvement in symptom) and positive values indicate increase in side effects (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 2.61 | 5.35 | 7.46 | 6.89 | 7.30 |
| Pomalidomide Plus Low-Dose Dexamethasone | 2.71 | 3.26 | 3.73 | 4.74 | 4.55 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -3.75 | -2.36 | -3.03 | 0.00 | -0.93 |
| Pomalidomide Plus Low-Dose Dexamethasone | 0.52 | 2.67 | 0.80 | 0.51 | -2.51 |
The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Disease Symptoms Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction (i.e. improvement) in symptoms and positive values indicate increase (i.e. worsening) of symptoms. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -1.07 | 0.97 | 1.35 | 1.48 | 2.12 |
| Pomalidomide Plus Low-Dose Dexamethasone | -0.50 | -1.36 | -1.15 | -0.53 | 0.60 |
"EQ-5D is a self-administered questionnaire that assesses health-related quality of life (QOL). The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where an EQ-5D score of 1.00 equals perfect health, a score of 0 equals death and a score of -0.59 equals worst imaginable health state. A positive change from Baseline score indicates improvement in health status. A negative change from Baseline score indicates worsening in health status. Negative scores represent the possible though unlikely situation that a patient's QOL is worse than death, i.e. they would rather be dead than living with that QOL" (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -0.02 | -0.06 | -0.07 | -0.04 | -0.12 |
| Pomalidomide Plus Low-Dose Dexamethasone | -0.03 | 0.01 | 0.04 | 0.01 | 0.03 |
An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death. (NCT01311687)
Timeframe: From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3-4 adverse events | AE related to pomalidomide | AE related to dexamethasone | AE related to either study drug | Grade 3-4 AE related to pomalidomide | Grade 3-4 AE related to dexamethasone | Grade 3-4 AE related to either study drug | Grade 5 adverse events | Serious adverse events (SAEs) | SAE related to pomalidomide | SAE related to dexamethasone | SAE related to either study drug | SAE leading to discontinuation of pomalidomide | SAE leading to discontinuation of dexamethasone | SAE leading to discontinuation of either study dru | AE leading to discontinuation of pomalidomide | AE leading to discontinuation of dexamethasone | AE leading to discontinuation of either study drug | |
| HD-Dex / Pomalidomide | 11 | 8 | 11 | 5 | 11 | 6 | 2 | 6 | 1 | 4 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| High-Dose Dexamethasone | 149 | 127 | 0 | 115 | 115 | 0 | 70 | 70 | 21 | 80 | 0 | 36 | 36 | 0 | 14 | 14 | 0 | 16 | 16 |
| Pomalidomide Plus Low-Dose Dexamethasone | 298 | 266 | 251 | 205 | 271 | 199 | 114 | 212 | 46 | 195 | 89 | 73 | 98 | 20 | 20 | 23 | 30 | 34 | 38 |
Time to worsening in quality of life domains was calculated as the time from Baseline to the first worsened minimally important difference (MID), defined as the smallest change in a QOL score considered important to patients that would lead the patient or clinician to consider a change in therapy. MID thresholds were calculated in Standard Error of Measurement (SEM) units using the Baseline QOL data. Based on the MID, participants were classified as worsened according to the following: For the EORTC QLQ-C30 global health status and functional scales and the EQ-5D health utility score, participants were classified as worsened if their change from Baseline score was less than -1 SEM. For the EORTC QLQ-C30 symptom scores (fatigue and pain) and EORTC QLQ-MY20 disease symptoms and side effects scales, participants were classified as worsened if their change from Baseline score was greater than 1 SEM. See previous outcome measures for definitions of each scale. (NCT01311687)
Timeframe: Assessed on Day 1 of the first 6 treatment cycles.
| Intervention | days (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Global Health Status | Physical Functioning | Emotional Functioning | Fatigue | Pain | Disease Symptoms | Side Effects of Treatment | Health Utility | |
| High-Dose Dexamethasone | 57 | 67 | 85 | 57 | 85 | 106 | 85 | 162 |
| Pomalidomide Plus Low-Dose Dexamethasone | 71 | 128 | 146 | 58 | 92 | 127 | 90 | 225 |
Response is assessed by investigator according to International Working Group (IWG) criteria. A complete response requires disappearance of all evidence of disease. A partial response is a >/= 50% decrease in the sum of products of 6 largest dominant nodes or nodal masses as well as for splenic and hepatic nodules. No increase in size of nodes, liver or spleen and no new sites of disease. (NCT00238238)
Timeframe: Duration of treatment (12 cycles)
| Intervention | percentage of participants (Number) |
|---|---|
| Arm II - Lenalidomide | 53.3 |
| Arm III - Lenalidomide and Rituximab | 76.1 |
Time to progression (TTP) is defined as the time from study entry until progression or death without progression. The median TTP with 95% CI was estimated using the Kaplan-Meier method. (NCT00238238)
Timeframe: Up to 10 years
| Intervention | years (Median) |
|---|---|
| Arm II - Lenalidomide | 1.1 |
| Arm III - Lenalidomide and Rituximab | 2 |
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 39.1 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 31.5 |
| Lenalidomide and Dexamethasone Rd18 | 21.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.1 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 35.0 |
| Lenalidomide and Dexamethasone Rd18 | 22.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.3 |
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive. (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 59.1 |
| Lenalidomide and Dexamethasone Rd18 | 62.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 49.1 |
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 36.7 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 26.0 |
| Lenalidomide and Dexamethasone Rd18 | 21.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.9 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 25.5 |
| Lenalidomide and Dexamethasone Rd18 | 20.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 70.0 |
| Lenalidomide and Dexamethasone Rd18 | 69.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 58.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 81.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 70.6 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of particpants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 74.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 61.0 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 60.5 |
| Lenalidomide and Dexamethasone Rd18 | 76.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 57.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 46.2 |
| Lenalidomide and Dexamethasone Rd18 | 53.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 45.7 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.7 |
| Lenalidomide and Dexamethasone Rd18 | 78.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 67.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 75.1 |
| Lenalidomide and Dexamethasone Rd18 | 73.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 62.3 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.9 | -3.3 | -8.6 | -6.4 | -5.1 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.3 | -5.9 | -9.8 | -7.3 | -8.1 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | -6.2 | -13.5 | -10.5 | -12.2 | -2.6 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.7 | 1.8 | 0.9 | -1.2 | -2.8 | -2.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.2 | -0.7 | -0.9 | -1.6 | -2.2 | -4.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.8 | -1.5 | -0.3 | -0.6 | -0.7 | -7.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 6.3 | 0.0 | -5.1 | -5.2 | -5.9 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 8.3 | 1.8 | -2.4 | -2.4 | -4.5 | -7.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 18.4 | 13.9 | 6.8 | 3.7 | 0.0 | -2.2 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.3 | 3.4 | 6.0 | 9.1 | 10.9 | 6.4 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 3.8 | 3.7 | 8.2 | 11.8 | 14.8 | 10.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.6 | -2.4 | -2.2 | -2.5 | -1.7 | -0.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.6 | -1.9 | -2.9 | -1.6 | 2.9 | 0.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.9 | -0.8 | -2.3 | -3.5 | -1.8 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.2 | 2.0 | 0.1 | -1.6 | 0.4 | 7.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 0.1 | 3.9 | 5.8 | 4.9 | 3.1 | 3.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.6 | 3.8 | 4.6 | 4.6 | 5.8 | 2.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 2.1 | 5.5 | 5.1 | 5.1 | -0.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.4 | -3.4 | -5.9 | -2.3 | 0.1 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.6 | -2.5 | -3.7 | -4.3 | -3.1 | 0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 | -1.8 | -4.5 | -3.9 | -4.3 | 2.7 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.3 | -0.4 | -0.3 | 1.6 | 1.8 | 0.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 1.9 | 1.4 | 0.4 | 2.0 | 1.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.5 | 1.9 | 0.7 | 1.1 | 0.4 | 5.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.2 | -1.3 | -1.9 | 1.1 | 1.4 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 0.2 | -1.2 | -1.0 | -0.5 | -5.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -10.5 | -8.9 | -11.6 | -9.6 | -6.0 | -4.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.5 | -2.5 | -4.0 | -3.6 | -2.7 | -4.2 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 | -1.1 | -1.3 | -2.2 | -2.3 | 0.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.0 | -1.2 | -3.9 | -3.9 | -3.9 | 1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.4 | -13.1 | -16.1 | -14.7 | -12.4 | -7.9 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -5.4 | -13.4 | -14.4 | -14.0 | -14.4 | -8.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | -7.8 | -12.1 | -13.4 | -14.3 | -14.7 | -6.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.4 | 4.7 | 7.6 | 7.4 | 6.8 | 3.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.7 | 3.4 | 4.7 | 5.0 | 6.9 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.9 | 2.2 | 5.3 | 6.9 | 8.3 | -0.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.6 | 6.3 | 8.6 | 9.4 | 9.1 | 3.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -2.7 | 2.4 | 6.3 | 7.8 | 8.0 | -0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | -2.4 | 4.1 | 8.2 | 11.8 | 14.5 | -1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -2.2 | 2.0 | 5.2 | 3.8 | 3.2 | 2.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.3 | 0.7 | 4.0 | 2.9 | 4.2 | -1.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.4 | 2.4 | 3.4 | 5.8 | 6.0 | -3.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Study discontinuation | |
| Lenalidomide and Dexamethasone Rd18 | -1.3 | 4.7 | 5.4 | 3.2 | 5.7 | 5.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.4 | 4.8 | 5.9 | 4.8 | 6.4 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 4.3 | 6.1 | 6.5 | 4.8 | 0.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.5 | 0.8 | 1.5 | -0.4 | -0.3 | 1.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.5 | -1.7 | -1.4 | -1.4 | -2.3 | -5.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.6 | -3.0 | -2.8 | -2.6 | -1.1 | -5.6 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s). (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.1 | -10.0 | -9.9 | -8.7 | -6.2 | -4.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.0 | -9.1 | -8.8 | -7.8 | -8.7 | -3.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | -4.4 | -7.0 | -7.9 | -6.5 | -7.9 | -3.7 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.9 | 9.2 | 12.3 | 12.1 | 11.7 | 8.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 4.7 | 8.5 | 9.8 | 10.8 | 12.7 | 5.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 3.3 | 6.3 | 8.0 | 10.0 | 9.5 | 3.2 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.0 | 1.2 | -0.4 | 1.2 | 2.3 | -1.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.5 | 1.0 | 1.7 | 1.9 | 2.2 | 0.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 5.6 | 3.5 | 2.9 | 4.7 | 4.3 | 3.8 |
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. (NCT00689936)
Timeframe: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 adverse event (AE) | ≥ 1 grade (Gr) 3 or 4 AE | ≥ 1 grade (Gr) 5 AE | ≥ 1 serious adverse event (SAE) | ≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal | ≥ 1 AE related to Lenalidomide | ≥ 1 AE related to dexamethasone | ≥ 1 AE related to melphalan | ≥ 1 AE related to prednisone | ≥ 1 AE related to thalidomide | ≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal | ≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 grade 3 or 4 AE related to Lenalidomide | ≥ 1 grade 3 or 4 AE related to dexamethasone | ≥ 1 grade 3 or 4 AE related to melphalan | ≥ 1 grade 3 or 4 AE related to prednisone | ≥ 1 grade 3 or 4 AE related to Thalidomide | ≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Lenalidomide | ≥ 1 Grade 5 AE related to Dexamethasone | ≥ 1 Grade 5 AE related to melphalan | ≥ 1 Grade 5 AE related to prednisone | ≥ 1 Grade 5 AE related to Thalidomide | ≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal | ≥1 SAE related to Len/Dex/Mel/Pred/Thal | ≥1 SAE related to Lenalidomide | ≥1 SAE related to dexamethasone | ≥1 SAE related to melphalan | ≥1 SAE related to prednisone | ≥1 SAE related to thalidomide | ≥1 SAE related to Len/Dex or Mel/Pred/Thal | ≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal | ≥1 AE leading to Lenalidomide withdrawal | ≥1 AE leading to dexamethasone withdrawal | ≥1 AE leading to melphalan withdrawal | ≥1 AE leading to prednisone withdrawal | ≥1 AE leading to Thalidomide withdrawal | ≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal | ≥1AE leading to Len/Dex/Mel/Pred/Thal reduction | ≥1 AE leading to Lenalidomide reduction | ≥1 AE leading to dexamethasone reduction | ≥1 AE leading to melphalan reduction | ≥1 AE leading to prednisone reduction | ≥1 AE leading to thalidomide reduction | ≥1AE leading to Len/Dex or Mel/Pred/Thal reduction | ≥1 AE leading to Rd or MPT interruption | ≥1 AE leading to Lenalidomide interruption | ≥1 AE leading to dexamethasone interruption | ≥1 AE leading to melphalan interruption | ≥1 AE leading to prednisone interruption | ≥1 AE leading to Thalidomide interruption | ≥1 AE leading to Len and Dex or MPT interruption | |
| Lenalidomide and Dexamethasone Rd18 | 536 | 433 | 36 | 308 | 501 | 481 | 410 | 0 | 0 | 0 | 269 | 326 | 290 | 177 | 0 | 0 | 0 | 104 | 11 | 9 | 7 | 0 | 0 | 0 | 5 | 158 | 130 | 97 | 0 | 0 | 0 | 64 | 109 | 93 | 104 | 0 | 0 | 0 | 84 | 214 | 155 | 118 | 0 | 0 | 0 | 20 | 321 | 301 | 280 | 0 | 0 | 0 | 241 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 529 | 453 | 50 | 359 | 506 | 482 | 429 | 0 | 0 | 0 | 269 | 373 | 342 | 229 | 0 | 0 | 0 | 131 | 17 | 12 | 16 | 0 | 0 | 0 | 11 | 195 | 165 | 130 | 0 | 0 | 0 | 95 | 157 | 109 | 152 | 0 | 0 | 0 | 96 | 279 | 203 | 170 | 0 | 0 | 0 | 30 | 368 | 353 | 319 | 0 | 0 | 0 | 290 |
| Melphalan + Prednisone + Thalidomide (MPT) | 539 | 480 | 38 | 270 | 527 | 0 | 0 | 441 | 326 | 493 | 145 | 423 | 0 | 0 | 307 | 118 | 316 | 49 | 10 | 0 | 0 | 6 | 5 | 5 | 2 | 142 | 0 | 0 | 75 | 62 | 94 | 27 | 153 | 0 | 0 | 83 | 78 | 146 | 71 | 348 | 0 | 0 | 199 | 47 | 254 | 2 | 419 | 0 | 0 | 328 | 324 | 388 | 249 |
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline Grade | Grade 4 Baseline to Grade 1 postbaseline Grade | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline Grade to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 133 | 85 | 109 | 71 | 30 | 6 | 11 | 15 | 30 | 4 | 0 | 1 | 11 | 18 | 5 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 103 | 96 | 121 | 70 | 21 | 7 | 8 | 17 | 25 | 9 | 1 | 1 | 14 | 18 | 9 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 37 | 79 | 128 | 141 | 45 | 2 | 2 | 11 | 20 | 21 | 0 | 1 | 7 | 21 | 10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CrCl< 30 mL/min to CrCl< 30 mL/min | CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl< 30 mL/min to ≥ 80 mL/min | CrCl≥ 30 but < 50 mL/min to < 30 mL/min | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL | CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min | CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min | CrCl ≥ 80 mL/min to CrCl< 30 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min | |
| Lenalidomide and Dexamethasone Rd18 | 17 | 14 | 8 | 2 | 2 | 41 | 55 | 12 | 0 | 1 | 130 | 99 | 1 | 0 | 10 | 114 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 15 | 18 | 7 | 2 | 1 | 37 | 67 | 9 | 0 | 4 | 112 | 107 | 0 | 0 | 6 | 109 |
| Melphalan + Prednisone + Thalidomide (MPT) | 19 | 19 | 5 | 0 | 0 | 41 | 65 | 2 | 0 | 4 | 102 | 97 | 0 | 0 | 9 | 121 |
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade 1 Baseline to Grade 1 postbaseline | Grade1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline | Grade 4 Baseline to Grade 1 postbaseline | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 10 | 30 | 8 | 1 | 0 | 0 | 126 | 123 | 17 | 5 | 0 | 12 | 135 | 41 | 9 | 0 | 1 | 4 | 8 | 3 | 0 | 0 | 0 | 1 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 6 | 39 | 8 | 0 | 0 | 0 | 106 | 128 | 25 | 2 | 0 | 8 | 125 | 48 | 4 | 0 | 0 | 12 | 10 | 5 | 0 | 0 | 0 | 0 | 1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 9 | 25 | 4 | 1 | 0 | 0 | 110 | 123 | 20 | 4 | 0 | 14 | 133 | 47 | 11 | 0 | 0 | 10 | 10 | 2 | 0 | 0 | 1 | 0 | 2 |
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade1 Baseline to Normal postbaseline Grade | Grade 1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline Grade | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline Grade | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 197 | 211 | 30 | 12 | 5 | 3 | 38 | 19 | 12 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 197 | 216 | 24 | 15 | 4 | 1 | 34 | 15 | 10 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 165 | 208 | 27 | 31 | 11 | 6 | 51 | 7 | 10 | 1 | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 1 | 1 | 0 |
The primary objective is progression-free survival (PFS). Tumor measurements and disease assessments will be performed at the time of screening, following cycles 3 and 6 of induction chemotherapy, every 4 cycles during the maintenance portion of treatment, and at the end of treatment (EOT). Subjects with clinical evidence of progression prior to a planned disease assessment will be evaluated at the time of clinically suspected progression. Follow-up visits for disease assessment will occur every 3 months after the EOT visit until PD, initiation of alternate anti-neoplastic therapy, decision by the subject to withdraw from the study, or death. The follow-up period will begin after the EOT visit, and all subjects will be followed for at least 2 years after completion of therapy or until death or progression and until the last patient has been followed for at least 1 year following completion of therapy. (NCT01754857)
Timeframe: At least 24 months following completion of therapy, an average of 5 years
| Intervention | years (Median) |
|---|---|
| Bendamustine, Rituximab, Lenalidomide | 4.76 |
To determine toxicities observed with induction chemotherapy and maintenance therapy. Safety evaluations will be based on the incidence, intensity, and type of adverse events (AEs) and clinical laboratory results. Drug doses will be modified as required based on toxicity as assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. (NCT01754857)
Timeframe: Up to 30 months
| Intervention | toxicity related events (Number) | |
|---|---|---|
| Serious Adverse Events due to toxicities | Adverse Events due to toxicities | |
| Bendamustine, Rituximab, Lenalidomide | 41 | 167 |
Duration of response was calculated for the responders as the time from the initial documented response (CR or VGPR or PR) to the first documented progression or death due to any cause, whichever occurred first. Duration of response for participants last known to be alive with no progression after a CR, VGPR, or PR were censored at the date of last adequate response assessment. (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July2014. Median follow up time was 61.6 weeks.
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
"Number of Complete Responses (CR) plus Very Good Partial Response (VGPR) plus Partial Response (PR) based on the International Myeloma Working Group criteria (IMWG). Any participant who achieved a CR, VGPR, or PR while on study treatment was defined as a responder.~CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required." (NCT01698801)
Timeframe: From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide Plus Dexamethasone | 87.5 |
The time from the start of study treatment to death due to any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow up is 14.2 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 17.71 |
PFS was calculated as the time from the first dose date to the first documented progression based on IWG criteria or death due to any cause, whichever occurred first. If progression or death was not documented at the time of data cutoff date, these observations were censored at the last adequate assessment date showing evidence of no progression or death. (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow-up for PFS assessments was 61.6 weeks.
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
"Time to response was calculated for the responders as the time from the first dose date to the initial documented response (CR, VGPR or PR).~CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required." (NCT01698801)
Timeframe: From the first dose of study drug treatment until the data cut-off date of 15 July 2014. Median follow-up time was 61.6 weeks.
| Intervention | months (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 1.97 |
An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required);-Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death. (NCT01698801)
Timeframe: From first dose of study drug treatment through to 28 days after the last dose, until the data cut-off date of 15 July 2014; median treatment duration was 60 weeks
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | TEAE related to study drug | TEAE related to Lenalidomide | TEAE related to Dexamethasone | Grade 3-4 adverse event | Grade 3-4 adverse event related to any study drug | Grade 3-4 adverse event related to Lenalidomide | Grade 3-4 adverse event related to Dexamethasone | Serious TEAE | Serious TEAE related to any study drug | Serious TEAE related to Lenalidomide | Serious TEAE related to Dexamethasone | TEAE leading to discontinuation of either drug | TEAE leading to discontinuation of lenalidomide | TEAE leading to discontinuation of dexamethasone | Related TEAE discontinuation of either drug | Related TEAE discontinuation of lenalidomide | Related TEAE discontinuation of dexamethasone | |
| Lenalidomide Plus Dexamethasone | 26 | 25 | 25 | 20 | 18 | 15 | 15 | 4 | 11 | 8 | 8 | 3 | 4 | 4 | 2 | 4 | 4 | 0 |
PFS was defined as the time from the first dose of study treatment to progressive disease (PD) or death due to any cause on study or within 28 days after study discontinuation, whichever occurred earlier. (NCT01724177)
Timeframe: From day 1 of study treatment to the date of disease progression; up to data cut date of date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 16.30 |
Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive. (NCT01724177)
Timeframe: From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 88.10 |
The response duration in participants with an objective response was measured from the date of the first Complete Response or Complete Response unconfirmed or Partial Response to the first date of Relapsed Disease or Progressive Disease (PD). For participants who did not progress during the study, DOR was censored at the last adequate response assessment not showing evidence of PD. (NCT01724177)
Timeframe: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; Maximum study duration was 134.1 Weeks
| Intervention | weeks (Number) |
|---|---|
| Lenalidomide | 24.10 |
Time to progression was calculated as the time from the first dosing of study treatment to the first documented PD and assessed by the ESEC (NCT01724177)
Timeframe: From day 1 of study treatment to the date of disease progression; up to data cut date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 16.30 |
The tumor control rate was measured for those with a response of Complete Remission, + CRu, + PR + Stable Disease (SD) in the EE population based on the best response. (NCT01724177)
Timeframe: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 73.1 |
"ORR is a Complete Response (CR) + Complete Response unconfirmed (CRu) + Partial Response (PR). A CR requires that target lesions have regressed to normal; nodal non-target lesions have regressed to normal; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are GR 0; peripheral blood is normal; Bone marrow (BM) infiltration is negative and no new lesions. A CRu requires the sum of the product diameters (SPD) of target lesions have decreased by at least 75% from baseline; nodal non-target lesions have regressed to normal size; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are Grade 0; peripheral blood is normal; BM infiltration is negative and no new lesions. A PR requires the SPD of target lesions has decreased by at least 50% from baseline; all nodal non-target lesions have regressed to normal or show no increase in size; all extranodal non-target lesions have disappeared" (NCT01724177)
Timeframe: From day 1 of study treatment to date of first documented CR, CRU or PR; Up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 42.3 |
Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR) (NCT01724177)
Timeframe: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 8.10 |
Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the start of study treatment and within 28 days after the last dose. Severity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Life-threatening and Grade 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. (NCT01724177)
Timeframe: From the date of the first dose of study drug up to 28 days after the last dose of study drug; up to data cutoff date of 19 May 2017; maximum treatment duration was 130.1 weeks
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 TEAE | ≥ 1 TEAE Related to Lenalidomide | ≥ 1 NCI CTCAE Grade (GR) 3 or Greater TEAE | ≥ 1 NCI CTCAE ≥ GR 3 TEAE Related to Lenalidomide | ≥ 1 Serious TEAE | ≥ 1 Serious TEAE Related to Lenalidomide | ≥ 1 TEAE Leading to Discontinuation | ≥ 1 Related TEAE Leading to Discontinuation | ≥ 1 TEAE Leading to Dose Reduction/Interruption | ≥ 1 related TEAE Leading to Decrease/Interruption | ≥ 1 TEAE Resulting in Death | |
| Lenalidomide | 26 | 26 | 25 | 25 | 11 | 9 | 8 | 8 | 17 | 17 | 0 |
"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment Failure/Progressive Disease | Partial Response | Complete Response | |
| Thalidomide + Bisphosphonate | 56 | 17 | 10 |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression. (NCT00424047)
Timeframe: Up to data cut off of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 67.6 |
| Placebo Plus Dexamethasone | 33.3 |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression. (NCT00424047)
Timeframe: Up to data cut off of 03 Mar 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 68.1 |
| Placebo Plus Dexamethasone | 33.3 |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT00424047)
Timeframe: Randomization to data cut off of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
| Placebo Plus Dexamethasone | NA |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT00424047)
Timeframe: Randomization to data cut off of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 161.9 |
| Placebo Plus Dexamethasone | 133.3 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia. (NCT00424047)
Timeframe: From randomization up to cut-off date of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 52.1 |
| Placebo Plus Dexamethasone | 20.1 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia. (NCT00424047)
Timeframe: From randomization up to cut-off date of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 52.4 |
| Placebo Plus Dexamethasone | 20.1 |
Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone). (NCT00424047)
Timeframe: Up to unblinding data cut off of 03 August 2005; up to 24 months
| Intervention | participants (Number) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
| Placebo Plus Dexamethasone | NA |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented. (NCT00424047)
Timeframe: Randomization to cut off date of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 10.1 |
| Placebo Plus Dexamethasone | 12.3 |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented. (NCT00424047)
Timeframe: Randomization to cut off date of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 10.1 |
| Placebo Plus Dexamethasone | 12.3 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma. (NCT00424047)
Timeframe: Randomization to data cut-off of 02 Mar 2008; up to 51 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluable (NE) those without response data | |
| Lenalidomide Plus Dexamethasone | 17.0 | 42.6 | 28.4 | 3.4 | 8.5 |
| Placebo Plus Dexamethasone | 4.0 | 19.4 | 56.6 | 14.3 | 5.7 |
"An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event.~The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death." (NCT00424047)
Timeframe: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 Adverse Event | ≥ 1 Serious Adverse Event | ≥ 1 AE leading to study drug discontinuation | ≥ 1 AE leading to dose reduction or interruption | ≥ 1 Drug-Related Adverse Event | ≥ 1 Drug-Related Serious Adverse Event | ≥Death within ≤ 30 days of last dose of study drug | ≥ 1 Grade 1 or Higher Adverse Event | ≥ 1 Grade 2 or Higher Adverse Event | ≥ 1 Grade 3 or Higher Adverse Event | ≥ 1 Grade 4 or Higher Adverse Event | |
| Lenalidomide Plus Dexamethasone | 176 | 105 | 46 | 137 | 160 | 54 | 17 | 176 | 168 | 146 | 52 |
| Placebo Plus Dexamethasone | 175 | 79 | 31 | 100 | 151 | 30 | 20 | 175 | 167 | 119 | 37 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma. (NCT00424047)
Timeframe: Randomization to 03 August 2005; up to 24 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluable (NE) those without response data | |
| Lenalidomide Plus Dexamethasone | 15.3 | 43.8 | 29.0 | 2.8 | 9.1 |
| Placebo Plus Dexamethasone | 4.0 | 19.4 | 56.6 | 14.3 | 5.7 |
The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens. (NCT00056160)
Timeframe: Up to Unblinding (07 Jun 2005)
| Intervention | Participants (Number) |
|---|---|
| CC-5013/Dex | 107 |
| Placebo/Dex | 34 |
Overall survival was calculated as the time from randomization to death from any cause. (NCT00056160)
Timeframe: 170 weeks (median overall survival of CC-5013/Dex treatment group)
| Intervention | Weeks (Median) |
|---|---|
| CC-5013/Dex | 170.1 |
| Placebo/Dex | 136.4 |
The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization. (NCT00056160)
Timeframe: 30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
| Intervention | Weeks (Mean) |
|---|---|
| CC-5013/Dex | 29.9 |
| Placebo/Dex | 15.0 |
Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123. (NCT00056160)
Timeframe: 60 weeks (median Time To Progression of CC-5013/Dex treatment group)
| Intervention | Weeks (Median) |
|---|---|
| CC-5013/Dex | 60.1 |
| Placebo/Dex | 20.1 |
Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. The median DOR with 95%CI was estimated using the Kaplan Meier method. (NCT00478218)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | 26.1 |
| LCD (Cyclophosphamide 300 mg) | NA |
"Response that was confirmed on 2 consecutive evaluations during treatment~Complete Response(CR): Complete disappearance of M-protein from serum & urine on immunofixation, normalization of Free Light Chain (FLC) ratio & <5% plasma cells in bone marrow (BM)~Very Good Partial Response(VGPR): >=90% reduction in serum M-component; Urine M-Component <100 mg per 24 hours; <=5% plasma cells in BM~Partial Response PR): >= 50% reduction in serum M-Component and/or Urine M-Component >= 90% reduction or <200 mg per 24 hours; or >= 50% decrease in difference between involved and uninvolved FLC levels" (NCT00478218)
Timeframe: Duration of Treatment (up to 5 years)
| Intervention | participants (Number) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | 28 |
| LCD (Cyclophosphamide 300 mg) | 16 |
OS was defined as the time from registration to death of any cause. Participants were followed for a maximum of 5 years from randomization. The median OS with 95%CI was estimated using the Kaplan Meier method. (NCT00478218)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | NA |
| LCD (Cyclophosphamide 300 mg) | NA |
"PFS was defined as the time from registration to progression or death due to any cause. The median PFS with 95%CI was estimated using the Kaplan Meier method.> Progression was defined as any one or more of the following:> An increase of 25% from lowest confirmed response in:>~Serum M-component (absolute increase >= 0.5g/dl)>~Urine M-component (absolute increase >= 200mg/24hour>~Difference between involved and uninvolved Free Light Chain levels (absolute increase >= 10mg/dl>~Bone marrow plasma cell percentage (absolute increase of >=10%)" (NCT00478218)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| LCD (Cyclophosphamide 300 mg/m^2) | 27 |
| LCD (Cyclophosphamide 300 mg) | NA |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 0.4 |
| Lenalidomide - Subpopulation From UK + Ireland | 3.3 |
| Lenalidomide - Subpopulation From Spain | -4.5 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -1.9 |
| Lenalidomide - Subpopulation From UK + Ireland | -4.9 |
| Lenalidomide - Subpopulation From Spain | 3.5 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.1 |
| Lenalidomide - Subpopulation From UK + Ireland | 7.9 |
| Lenalidomide - Subpopulation From Spain | 2.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 8.6 |
| Lenalidomide - Subpopulation From UK + Ireland | 8.1 |
| Lenalidomide - Subpopulation From Spain | 9.0 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.7 |
| Lenalidomide - Subpopulation From UK + Ireland | 2.7 |
| Lenalidomide - Subpopulation From Spain | -0.9 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -0.2 |
| Lenalidomide - Subpopulation From UK + Ireland | -4.0 |
| Lenalidomide - Subpopulation From Spain | -0.7 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.6 |
| Lenalidomide - Subpopulation From UK + Ireland | 5.3 |
| Lenalidomide - Subpopulation From Spain | 1.0 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.0 |
| Lenalidomide - Subpopulation From UK + Ireland | 0.8 |
| Lenalidomide - Subpopulation From Spain | 0.9 |
EORTQ QLC-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.1 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.8 |
| Lenalidomide - Subpopulation From Spain | -2.2 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.8 |
| Lenalidomide - Subpopulation From UK + Ireland | 2.2 |
| Lenalidomide - Subpopulation From Spain | -1.8 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.0 |
| Lenalidomide - Subpopulation From UK + Ireland | 0.1 |
| Lenalidomide - Subpopulation From Spain | -2.2 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.9 |
| Lenalidomide - Subpopulation From UK + Ireland | -5.2 |
| Lenalidomide - Subpopulation From Spain | -6.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.6 |
| Lenalidomide - Subpopulation From UK + Ireland | -2.9 |
| Lenalidomide - Subpopulation From Spain | -1.8 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -2.4 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.5 |
| Lenalidomide - Subpopulation From Spain | -2.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -5.2 |
| Lenalidomide - Subpopulation From UK + Ireland | -5.3 |
| Lenalidomide - Subpopulation From Spain | -3.1 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -4.3 |
| Lenalidomide - Subpopulation From UK + Ireland | -2.0 |
| Lenalidomide - Subpopulation From Spain | -5.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -2.4 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.2 |
| Lenalidomide - Subpopulation From Spain | -3.9 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 5.8 |
| Lenalidomide - Subpopulation From UK + Ireland | 3.4 |
| Lenalidomide - Subpopulation From Spain | 4.4 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 4.9 |
| Lenalidomide - Subpopulation From UK + Ireland | 4.7 |
| Lenalidomide - Subpopulation From Spain | 2.0 |
Time between first dose and when a TEAE for peripheral neuropathy was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide Plus Dexamethasone | 25.6 |
Time between first dose and when a TEAE for venous thromboembolic event was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide Plus Dexamethasone | 26.5 |
"Counts of study participants who had treatment-emergent adverse events (TEAEs) defined as any reported AE that started on or after the first day of study drug dosing. A participant with multiple occurrences of an adverse event within a category is counted only once in that category.~National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) was used by investigators to assess TEAEs. Severity scale ranges from 0 (none) to 5 (death). Grade 3=severe AE; Grade 4=life threatening or disabling AE; Grade 5=death." (NCT00420849)
Timeframe: up to 123 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| At least one treatment-emergent AE (TEAE) | At least one TEAE related to study drug | At least one TEAE with severity grade of 3 or 4 | At least one serious AE (SAE) | |
| Lenalidomide Plus Dexamethasone | 586 | 519 | 471 | 340 |
Number of participants with at least one peripheral neuropathy treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for peripheral neuropathy in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At least one TEAE of peripheral neuropathy | Neuropathy peripheral | Peripheral sensory neuropathy | Neuralgia | Peripheral motor neuropathy | Polyneuropathy | Sensory disturbance | |
| Lenalidomide Plus Dexamethasone | 84 | 46 | 33 | 5 | 2 | 2 | 1 |
Number of participants with at least one venous thromboembolic treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for venous thromboembolic events in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At least one venous thromboembolic event | Deep vein thrombosis | Pulmonary embolism | Thrombophlebitis | Venous thrombosis limb | |
| Lenalidomide Plus Dexamethasone | 60 | 38 | 23 | 7 | 1 |
PFS at 12 months is a dichotomized outcome indicating whether or not a participant was progression free (and alive) at 12 months from the date of randomization. (NCT00432458)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Arm I: Thal/ZLD | 30 |
| Arm II: ZLD | 18 |
Duration of response (DOR) is defined as the time from first documentation of response (CR, VGPR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method (NCT00432458)
Timeframe: time from start of response to progression (up to 5 years)
| Intervention | years (Median) |
|---|---|
| Arm I: Thal/ZLD | 3.3 |
"Response is defined as follows:~CR: Complete disappearance of M-protein from serum & urine on immunofixation, <5% plasma cells in bone marrow (BM)~VGPR: >=90% reduction in serum M-component; Urine M-Component <100 mg per 24 hours; <=5% plasma cells in BM~PR: >= 50% reduction in serum M-Component and/or Urine M-Component >= 90% reduction or <200 mg per 24 hours; or >= 50% decrease in difference between involved and uninvolved FLC levels" (NCT00432458)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Arm I: Thal/ZLD | 13 |
| Arm II: ZLD | 0 |
"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 2.~Description of Grades:~Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death" (NCT00432458)
Timeframe: During treatment (up to 5 years)
| Intervention | participants (Number) |
|---|---|
| Arm I: Thal/ZLD | 17 |
| Arm II: ZLD | 13 |
Time to disease progression (TTP) was defined as the time from randomization to the earliest documentation of disease progression. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method, a two-sided (stratified) log-rank test was calculated. (NCT00432458)
Timeframe: randomization to progression (up to 5 years)
| Intervention | years (Median) |
|---|---|
| Arm I: Thal/ZLD | 2.4 |
| Arm II: ZLD | 1.2 |
Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method (NCT00432458)
Timeframe: time from randomization to treatment failure (up to 5 years)
| Intervention | months (Median) |
|---|---|
| Arm I: Thal/ZLD | 16.5 |
| Arm II: ZLD | 11.1 |
"Renal response - > 50% decrease in daily 24 hour proteinuria, without worsening renal insufficiency.~Hepatic response - decrease of 2 centimeters or more of the liver span and/or decrease of the alkaline phosphatase by 50% if elevated at baseline.~Cardiac response - decrease of 2 millimeters or more in mean left ventricular wall thickness in patients with baseline wall thickness > 11 mm or a decrease in New York Heart Association heart failure class.~Autonomic nervous system response - resolution of orthostatic vital signs and symptoms, and resolution of symptoms of gastric atony or of functional ileus.~Gastrointestinal response - a greater than one grade improvement in diarrhea due to biopsy proven amyloid.~Peripheral nervous system response - resolution of clinical signs of peripheral neuropathy." (NCT00679367)
Timeframe: one year
| Intervention | number of organs stable or improved (Number) |
|---|---|
| Melphalan Revlimid and Dexamethasone | 10 |
Number of study participants removed from study treatment due to toxicities (NCT00679367)
Timeframe: One year
| Intervention | Participants (Count of Participants) |
|---|---|
| Melphalan Revlimid and Dexamethasone | 6 |
"Complete hematologic response: Absence of detectable monoclonal protein in serum or urine by immunofixation electrophoresis, bone marrow biopsy with less than 5% plasma cells without clonal dominance of kappa or lambda isotype, and normal serum free light chain assay.~Partial hematologic response: Amyloid patients have highly individualized measures of disease burden. For patients with detectable and quantifiable monoclonal marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells. For patients with a detectable monoclonal peak on serum or urine protein electrophoresis, a reduction in the peak height of 50% or more. For patients with quantifiable urinary kappa or lambda chain concentration, a 50% reduction in daily light chain excretion (concentration x 24 hour urine volume). For patients with an elevated serum free light chain assay, reduction of 50% or more." (NCT00679367)
Timeframe: one year
| Intervention | participants (Number) |
|---|---|
| Melphalan Revlimid and Dexamethasone | 7 |
Duration of response is defined as time from response to disease progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Here is the number of serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01675141)
Timeframe: 37 months and 12 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | 11 |
PFS is defined as the time from study entry until progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00103506)
Timeframe: Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)
| Intervention | Participants (Number) |
|---|---|
| Velcade (Bortezomib) Monotherapy | 105 |
| Doxil/Caelyx Plus Velcade (Bortezomib) | 120 |
The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive. (NCT00103506)
Timeframe: Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)
| Intervention | months (Median) |
|---|---|
| Velcade (Bortezomib) Monotherapy | 30.8 |
| Doxil/Caelyx Plus Velcade (Bortezomib) | 33.0 |
Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of >=25% from lowest level in Serum M-component or (the absolute increase must be >=0.5 gram per deciliter [g/dL]); Urine M component or (the absolute increase must be >=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase >10 mg/dL. Bone marrow plasma cell percentage >=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date. (NCT00103506)
Timeframe: Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])
| Intervention | Months (Median) |
|---|---|
| Velcade (Bortezomib) Monotherapy | 6.5 |
| Doxil/Caelyx Plus Velcade (Bortezomib) | 9.3 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
42 reviews available for thalidomide and Disease Exacerbation
| Article | Year |
|---|---|
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Surv | 2017 |
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Topics: Angiogenesis Inhibitors; Apoptosis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Cl | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progres | 2014 |
Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2014 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Ant | 2014 |
Pyoderma gangrenosum: a systematic review.
Topics: Anti-Inflammatory Agents; Arthritis; Dermatologic Agents; Diagnosis, Differential; Disease Progressi | 2014 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease | 2014 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Pr | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease P | 2015 |
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Len | 2016 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progr | 2016 |
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Dexamethasone; Diphosphonates; Disease Progression; Europe | 2016 |
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; | 2016 |
[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease Progressio | 2015 |
Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis.
Topics: Adolescent; Adult; Dapsone; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosu | 2017 |
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2017 |
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 5; Disease Progressio | 2017 |
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
Topics: Animals; B7-H1 Antigen; Disease Progression; Humans; Killer Cells, Natural; Lenalidomide; Multiple M | 2017 |
Myelodysplastic syndromes: biology and treatment.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosomes, Human, Pair 5; Disease Progression; Erythropo | 2009 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5 | 2009 |
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Disease Progression; Humans; I | 2009 |
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Topics: Anemia; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic | 2010 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Rare bladder tumors: caveat emptor.
Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myelo | 2010 |
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; | 2012 |
[New therapeutic targets in psoriatic arthritis].
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antirheum | 2012 |
Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
Topics: Animals; Cell Line; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; DNA Modifi | 2012 |
Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Progressi | 2012 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Prog | 2012 |
Inflammatory mediators and the failing heart: past, present, and the foreseeable future.
Topics: Animals; Antibodies, Monoclonal; Antirheumatic Agents; Clinical Trials as Topic; Cytokines; Disease | 2002 |
Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Disease Progression; Dis | 2003 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Hematopoietic cancer and angiogenesis.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Disease Progression; Endothelium, Vascular; Hematologic | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; C | 2004 |
Antiangiogenic strategies in neuroblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cyclohexanes; Disea | 2005 |
What's wrong with this patient? Primary systemic amyloidosis.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Diagnosis, Differential; Disease Progres | 2006 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; | 2007 |
A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma.
Topics: Disease Progression; Humans; Immunosuppressive Agents; Multiple Myeloma; Thalidomide; Treatment Outc | 2008 |
Treatment approaches for relapsing and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Hema | 2000 |
Management of Kaposi sarcoma: the role of interferon and thalidomide.
Topics: Antiviral Agents; Combined Modality Therapy; Cytokines; Disease Progression; HIV Infections; Humans; | 2001 |
127 trials available for thalidomide and Disease Exacerbation
| Article | Year |
|---|---|
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cohort Studies; Cytokines; Disease Progres | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Dise | 2020 |
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P | 2017 |
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
Topics: Aged; Angiogenesis Inhibitors; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free | 2017 |
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progr | 2017 |
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progr | 2017 |
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progr | 2017 |
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chromosomes, Human, Pair 5; Cytogenetics; Disease Progr | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; | 2017 |
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Humans; Lenalidomide; L | 2017 |
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dis | 2017 |
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunolo | 2018 |
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; A | 2018 |
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; D | 2013 |
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarr | 2013 |
Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Chronic Disease; Cough; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ca | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dise | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone | 2013 |
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarr | 2013 |
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Disease-Free Survival; Humans | 2014 |
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Hematopoietic Stem Cell Transplan | 2014 |
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms; | 2014 |
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2014 |
Chronic thalidomide and chemoembolization for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Live | 2014 |
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Disease Pro | 2015 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosph | 2015 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexameth | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug | 2016 |
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome | 2016 |
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2016 |
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.
Topics: Aged; Aged, 80 and over; Dexamethasone; Disease Progression; Female; Humans; Japan; Kaplan-Meier Est | 2016 |
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease P | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2017 |
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Endpoin | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2017 |
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Constipation; Di | 2008 |
Lenalidomide therapy for metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression | 2008 |
A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; F | 2008 |
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Ne | 2008 |
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diphosphonates; Disease Progression; Di | 2008 |
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; | 2009 |
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2008 |
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Doxorubici | 2009 |
Predicting durable remissions following thalidomide therapy for relapsed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2009 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug R | 2010 |
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineopla | 2010 |
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
Topics: Aged; Antineoplastic Agents; Constipation; Disease Progression; Disease-Free Survival; Drug Administ | 2010 |
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cluster Analysis; Cyclophosphamide; Dexamethasone; D | 2011 |
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progressi | 2010 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2011 |
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2011 |
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopla | 2011 |
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor | 2012 |
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineopla | 2012 |
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethas | 2012 |
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2012 |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin | 2012 |
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Drug | 2013 |
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic | 2013 |
Low-dose thalidomide in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Protocols; Carcinoma, Renal Cell; Disease Progr | 2012 |
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; | 2013 |
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Angiogenesis Inhibitors; Disease Progression; Endothelial Growth | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
[Single-agent thalidomide for advanced and refractory multiple myeloma].
Topics: Aged; Aged, 80 and over; Constipation; Disease Progression; Disorders of Excessive Somnolence; Femal | 2003 |
Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease Progression; | 2003 |
Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Constipation; Disease Progression; Female; Glioblastoma; Heada | 2004 |
Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexa | 2003 |
Phase II study of thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Humans; Lung Neoplasms; Male; Max | 2004 |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease | 2004 |
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2004 |
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Topics: Disease Progression; Disease-Free Survival; Female; Humans; Intercellular Adhesion Molecule-1; Inter | 2004 |
Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Disease Progression; Female; Humans | 2005 |
Thalidomide therapy and polyneuropathy in myeloma patients.
Topics: Action Potentials; Adult; Aged; Disease Progression; Female; Humans; Immunosuppressive Agents; Male; | 2005 |
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; | 2005 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2006 |
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, R | 2006 |
Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Female; Humans; Male; | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Disease Progression; | 2006 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diseas | 2007 |
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Dose-Response Relationship, D | 2006 |
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcino | 2007 |
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Cyclophosphamide; Dexamethasone; | 2007 |
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Disease Progressio | 2007 |
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Disease Progressio | 2007 |
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Disease Progressio | 2007 |
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amyloidosis; Dexamethasone; Disease Progressio | 2007 |
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Rin | 2006 |
Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients.
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship | 2007 |
Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Re | 2007 |
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2007 |
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Fe | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; | 2007 |
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progress | 2008 |
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Disease Progression; Dos | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxo | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Ther | 2008 |
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2008 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality T | 2000 |
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Anti-HIV Agents; Disease Progressio | 2000 |
Thalidomide as an anti-angiogenic agent in relapsed gliomas.
Topics: Adult; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Glioma; Humans; Middle Aged; N | 2001 |
The treatment of advanced renal cell cancer with high-dose oral thalidomide.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Constipation; Cyt | 2001 |
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Squamous C | 2001 |
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Endothelial Growth Factors | 2001 |
147 other studies available for thalidomide and Disease Exacerbation
| Article | Year |
|---|---|
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Cytokines; Disease Models, Animal; Disease Progression; Drug Repositioning | 2022 |
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; D | 2022 |
Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China.
Topics: Adult; Antirheumatic Agents; Biomarkers; Blood Sedimentation; C-Reactive Protein; China; Disease Pro | 2020 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Stud | 2020 |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Topics: Adolescent; Antineoplastic Agents, Immunological; Brain Neoplasms; Child; Disease Progression; Dose- | 2021 |
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Con | 2017 |
Clonal evolution in myelodysplastic syndromes.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Bone Marrow Cells; Clonal Evolution; Disease Manag | 2017 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2017 |
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease | 2017 |
Improvement in the Axial Symptoms and Magnetic Resonance Imaging Findings With Apremilast in Psoriatic Arthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Disease Progression; Humans; I | 2017 |
Metachronous solitary plasmacytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diphosphonates; Di | 2017 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantl | 2017 |
MicroRNA-105 is involved in TNF-α-related tumor microenvironment enhanced colorectal cancer progression.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2017 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progressio | 2018 |
Intraperitoneal injection of thalidomide alleviates early osteoarthritis development by suppressing vascular endothelial growth factor expression in mice.
Topics: Animals; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Injections, Intrap | 2018 |
Combination therapy for first relapse of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide | 2018 |
A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Fema | 2018 |
Extramedullary Manifestation of Multiple Myeloma in the Oral Cavity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Fata | 2018 |
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal | 2013 |
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Topics: Aged; Aged, 80 and over; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Diseas | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema.
Topics: Administration, Oral; Adult; Biopsy, Needle; Disease Progression; Dose-Response Relationship, Drug; | 2013 |
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dru | 2013 |
Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; D | 2014 |
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Topics: Aged; Chromosome Deletion; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomid | 2014 |
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2014 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Prog | 2014 |
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; | 2014 |
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human | 2014 |
Comparative cost-effectiveness models for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Di | 2014 |
Thalidomide influences atherogenesis in aortas of ApoE(-/-)/LDLR (-/-) double knockout mice: a nano-CT study.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Aortic Diseases; Aortography; Apolipoproteins E; Atheroscle | 2014 |
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pa | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cycl | 2014 |
Critical role of TNF-α in cerebral aneurysm formation and progression to rupture.
Topics: Aneurysm, Ruptured; Animals; Blood Pressure; Blood Vessels; Disease Models, Animal; Disease Progress | 2014 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Prolife | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boroni | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; | 2015 |
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human | 2015 |
Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hemophilia A; Hum | 2015 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; D | 2015 |
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethaso | 2015 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome | 2015 |
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Abe | 2015 |
Involvement of cytokines in the modulation and progression of renal fibrosis induced by unilateral ureteral obstruction in C57BL/6 mice: effects of thalidomide and dexamethasone.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Dexamethasone; Disease Models, Animal; Disease Progres | 2016 |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease | 2016 |
Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Immunologic Factors; Lenalidomi | 2016 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2015 |
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cy | 2016 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; | 2016 |
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neo | 2016 |
Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond.
Topics: Adult; Diagnosis, Differential; Disease Progression; Genetic Markers; Genetic Testing; Hematopoietic | 2016 |
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Ch | 2016 |
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Disease Progression; Female; | 2016 |
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Consolidation Chemotherapy; Disea | 2017 |
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Topics: Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Computational | 2017 |
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; | 2017 |
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Antineoplastic Combined Chemotherapy Protocols; B-Lym | 2016 |
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Prog | 2017 |
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, H | 2017 |
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Di | 2008 |
Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury.
Topics: Animals; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme-Linked Immun | 2009 |
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Topics: Animals; Disease Models, Animal; Disease Progression; Gene Expression Profiling; Humans; Immunologic | 2009 |
Prostate cancer: thalidomide for prostate cancer: is there progress?
Topics: Clinical Trials as Topic; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Prostat | 2009 |
Hematology: Thalidomide maintenance in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 13; Clinical Trials, Phase | 2009 |
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Chromosome Banding; Chromosome Deletion; Chromosomes | 2009 |
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression | 2010 |
Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progre | 2009 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; De | 2009 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate U | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neop | 2011 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; D | 2010 |
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Lenalidomide: an update on evidence from clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Pro | 2010 |
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; D | 2011 |
Myelodysplastic syndrome presenting as generalized granulomatous dermatitis.
Topics: Aged; Antineoplastic Agents; Biopsy; Blood Cell Count; Dermatitis; Disease Progression; Granuloma; H | 2011 |
Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2012 |
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; | 2011 |
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; | 2012 |
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Dis | 2012 |
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; C | 2011 |
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2012 |
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Topics: Clinical Trials as Topic; Disease Progression; DNA Methylation; DNA, Neoplasm; Drugs, Investigationa | 2012 |
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Prog | 2012 |
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2013 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DN | 2012 |
Acquired EVI1 rearrangement involved in the transformation from 5q- syndrome to pre-B lymphocytic leukemia in a Chinese patient.
Topics: Adult; Anemia, Macrocytic; Blood Transfusion; Bone Marrow; Cell Differentiation; Cell Lineage; Chrom | 2012 |
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; CD4-Positive T-Lymphocytes; Cyclophosphamide; | 2012 |
Late-onset neurological symptoms in thalidomide-exposed subjects: a study of an Australasian cohort.
Topics: Antiemetics; Australasia; Australia; Cohort Studies; Disease Progression; Female; Humans; Male; Midd | 2013 |
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B | 2013 |
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2002 |
Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Topics: Angiogenesis Inhibitors; Disease Progression; Endothelial Growth Factors; Fibroblast Growth Factor 2 | 2002 |
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration | 2003 |
Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions.
Topics: Animals; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Cell Transformation, Neoplastic; Clinical Tr | 2003 |
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Disease Progres | 2002 |
Protective effect of thalidomide on endotoxin-induced liver injury.
Topics: Animals; Calcium; Disease Progression; Escherichia coli; Immunosuppressive Agents; Kupffer Cells; Li | 2003 |
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression | 2003 |
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide.
Topics: Biomarkers; Disease Progression; Follow-Up Studies; Humans; Immunosuppressive Agents; Membrane Prote | 2003 |
Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Interfero | 2004 |
Stabilization of a progressive hemangioblastoma under treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Cerebellar Neoplasms; Disease Progression; Female; Hemangioblastoma; Humans | 2004 |
Discordant response or progression in patients with myeloma treated with thalidomide-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Mye | 2004 |
Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases.
Topics: Aged; Aged, 80 and over; Cell Differentiation; Disease Progression; Fatal Outcome; Female; Humans; M | 2004 |
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
Topics: Aged; Cell Division; Disease Progression; Drug Resistance; Humans; Integrin alpha5; Male; Multiple M | 2004 |
Novel immunomodulatory therapies in the treatment of multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Immunosu | 2004 |
Thalidomide neuropathy in childhood.
Topics: Action Potentials; Adolescent; Brain Neoplasms; Child; Crohn Disease; Disease Progression; Electromy | 2005 |
Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; H | 2004 |
New strategies for MGUS and smoldering multiple myeloma.
Topics: Diphosphonates; Disease Management; Disease Progression; Drug Design; Humans; Immunoglobulin kappa-C | 2004 |
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Disease Progression; Dose-Respons | 2005 |
Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Drug Ther | 2005 |
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combin | 2005 |
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Clinical Trials, Phase | 2005 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy | 2006 |
Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c mice.
Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Disease Models, Animal; Disease Progression; Drug Th | 2006 |
Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases.
Topics: Arachnoiditis; Blindness; Brain; Child; Child, Preschool; Disease Progression; Drug Therapy, Combina | 2006 |
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Disease Progres | 2006 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug | 2006 |
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2006 |
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexam | 2007 |
Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Case-Control Studies; Di | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2007 |
Recto-vaginal fistula: a refractory complication of Behcet's disease.
Topics: Adult; Antibodies, Monoclonal; Behcet Syndrome; Dapsone; Disease Progression; Female; Humans; Inflam | 2007 |
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemot | 2007 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2007 |
Spinal epidural lipomatosis in myeloma.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Dexamethasone; Disease Progression; Humans; Lenalido | 2007 |
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexameth | 2008 |
Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
Topics: Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2008 |
Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis.
Topics: Disease Progression; Humans; Models, Neurological; Multiple Sclerosis; Thalidomide; Tumor Necrosis F | 1999 |
Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Disease Progression; Humans; Im | 2001 |
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl | 2001 |
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |